CMSS/PROC/2022-23/NVBDCP/031

ONLINE TENDER

FOR PROCUREMENT OF Inj. Artesunate, ACT AL Drugs & ACT SF Drugs FOR NVBDCP FOR THE YEAR 2022-23

Tender No: CMSS/PROC/2022-23/NVBDCP/031 (National Competitive Bidding) (FOR CLASS-1 and CLASS-II LOCAL SUPPLIERS ONLY)

CENTRAL MEDICAL SERVICES SOCIETY

Ministry of Health & Family Welfare (Government of India) 2nd Floor, Vishwa Yuvak Kendra, Pandit Uma Shankar Dikshit Road, Chanakyapuri, New Delhi-110021 Ph -: +91-11-21410905, +91-11-21410906 Email: - <u>gmproc.cmss@gmail.com</u>, <u>agminderjeetyadav.cmss@gmail.com</u>

CMSS/PROC/2022-23/NVBDCP/031

This page is intentionally left blank

CENTRAL MEDICAL SERVICES SOCIETY

Ministry of Health and Family Welfare(Government of India) 2nd Floor, Vishwa Yuvak Kendra, Pandit Uma Shankar Dikshit Road, Chanakyapuri, New Delhi-110021

Ph -: +91-11-21410905, +91-11-21410906 Email: <u>gmproc.cmss@gmail.com</u> <u>agminderjeetyadav.cmss@gmail.com</u>

ONLINE BIDS ARE INVITED IN TWO PACKET BID SYSTEM FOR Inj. ARTESUNATE, ACT AL & ACT SP DRUGS FOR NVBDCP FOR THE YEAR 2022-23

Manual bids shall not be accepted.

BID DOCUMENTS MAY BE DOWNLOADED FROM CPPP WEBSITE: https://eprocure.gov.in/eprocure/app AS PER THE SCHEDULE AS GIVEN IN CRITICAL DATE SHEET AS UNDER:

CRITICAL DATE SHEET

Published Date and Time	06.02.2023 at 05:00 p.m.
Bid Document Download Start Date and	06.02.2023 at 05:30 p.m.
Pre bid meeting	13.02.2023 at 11:00 p.m.
Last Date to submit Pre-Bid queries	13.02.2023 at 05:00 p.m.
Bid Submission Start Date and Time	20.02.2023 at 11:00 a.m.
Bid Document Download End Date & time	27.02.2023 at 4:00 p.m.
Bid Submission End Date and Time	27.02.2023 at 4:00 p.m.
Last Date of Submission of Original	28.02.2023 at 3:00 p.m.
Bid Opening Date and Time	28.02.2023 at 4:00 p.m.

Bids shall be submitted online only at CPPP website: <u>https://eprocure.gov.in/ eprocure/app</u>. Bidder/Contractor is advised to follow the instructions provided in the 'Instructions to the Contractors/Bidder for the e-submission of the bids online through the Central Public Procurement Portal for e Procurement at <u>https://eprocure.gov.in/eprocure/app'</u>.

Bid documents may be scanned with 100 dpi with black and white option which helps in reducing size of the scanned document. Not more than one bid shall be submitted by one contractor or contractors having business relationship.

Address for Communication :

Central Medical Services Society, 2nd Floor, VishwaYuvak Kendra, Pandit Uma Shankar Dikshit Road, Chanakyapuri, New Delhi-110021

This page is intentionally left blank

CONTENTS

SI. No.	Descriptions
1.	Last Date for Receipt of Tender
2.	Bid Validity
3.	Pre-Bid Meeting / Clarification
4.	Eligibility Criteria
5.	General Conditions
6.	Technical Bid – Packet 1
7.	Price Bid – Packet 2
8.	Opening of "Packet1" i.e. Technical Bid and Packet 2" i.e. Financial Bid of Tender
9.	Earnest Money Deposit
10.	Other Conditions
11.	Acceptance of Tender
12.	Security Deposit and Agreement
13.	Methodology for Placing Order
14.	Supply/Delivery Conditions
15.	Packing
16.	Quality Control
17.	Payment Provisions
18.	Liquidated Damages and other Penalties
19.	Warranty
20.	Deduction and other Penalties on account of Delays /Default/ Termination / Part Cancellation /short closure
21.	Saving Clause
22.	Prohibition of Influencing CMSS by the Bidder
23.	Resolution of Disputes
24.	Jurisdiction

CMSS/PROC/2022-23/NVBDCP/031

This page is intentionally left blank

LIST OF ANNEXURES

S. No.	Description
	Annex-I (Schedule of Requirement & Technical Specifications)
	Annex-II (Format of Forwarding Letter)
	Annex-III (Details of EMD Submitted)
	Annex-IV (Proforma for Performance Statement)
	Annex-V (Annual Turnover Statement)
	Annex-VI (List of Items Quoted & Their Production Capacity)
	Annex-VII (Check List)
	Annex-VIII (Notarized Undertaking by MSEs for EMD Exemption)
	Annex-IX (Letter of Acceptance)
	Annex- X (Long Term Agreement)
	Annex- XI (Purchase Order)
	Annex- XII (Mandate Form for RTGS)
	Annex- XIII (The Price Bid)
	Annex- XIV(Bank Guarantee for EMD (Format)
	Annex- XV (Security Bank Guarantee Format)
	Annex- XVI (Instruction for Online Bids Submission)
	Annex- XVII (No Deviation Certificate)
	Annex- XVIII (Near Relative Format)
	Annex-XIX (Format For Local Content Declaration)
	Annex-XX (Undertaking for Compliance to Ministry of Finance, DOE order No- 6/18/2019-PPD dated 23.07.2020)
	Annex- XXI (Consignee Receipt Certificate)

Annex- XXI (Consignee Receipt Certificate)

This page is intentionally left blank

CMSS/PROC/2022-23/NVBDCP/031

ONLINE TENDER FOR THE SUPPLY OF Inj. ARTESUNATE, ACT AL DRUGS & ACT SP DRUGS FOR NVBDCP For The Year 2022-23

The CMSS, an autonomous Society of Ministry of Health & Family Welfare (Govt. of India), is responsible for procuring quality drugs, vaccines, contraceptives, medical devices, diagnostic kits and other health sector goods.

Tender Inviting Authority: DG&CEO, Central Medical Services Society, Ministry of Health & Family Welfare (Government of India)2nd floor, Vishwa Yuvak Kendra, Pt. Uma Shankar Dikshit Marg, Teen Murti Road, Opposite Police Station Chankaya Puri, New Delhi-110021 (hereinafter referred as Tender Inviting Authority unless the context other wise requires).

Tender Accepting Authority: Governing Body, Central Medical Services Society (hereinafter referred as CMSS, unless the context otherwise requires)

Tender Inviting Authority invites tender through online bid submission at CPPP website: <u>https://eprocure.gov.in/eprocure/app</u> for supply of Drugs to Central Medical Services Society for the year 2022-23.

The list of items to be quoted and their specifications are given in Annexure- I.

Bidders are requested to submit all documents with the bid as shown as checklist (Annexure - VII). NO CLARIFICATIONS may be sought from bidders and incomplete bid may be summarily rejected at sole responsibility of bidder(s). CMSS decision in this regard will be final and binding.

1. LAST DATE FOR RECEIPT OF TENDER

Online Tenders (in two separate packets {Technical bid "Packet 1" and Price Bid "Packet 2"} will be submitted online at CPPP website: <u>https://eprocure.gov.in/eprocure/app</u> as per critical date sheet. The list of items along with their Technical Specifications are attached here as Annexure-I.

2. BID VALIDITY:

- i) The bid shall be valid for a period of 150 days from the date of opening of Packet 1 (Technical Bid).
- ii) In exceptional circumstances, the purchaser may request the consent of the bidder for an extension to the period of bid validity. The request and the responses there to shall be made in writing. The bid security provided under clause 9 shall also be suitably extended. A bidder may refuse the request without forfeiting his bid security. A bidder accepting the request and granting extension will not be permitted to modify his bid.

3. PRE BID MEETING/CLARIFICATIONS:

- i) A prospective bidder, requiring any clarification of the bid documents may notify the purchaser in writing or email at the purchaser's mailing address indicated in the Invitation of bid. The purchaser shall respond in writing (to be uploaded on CPPP and on e-procurement website) to any request for clarification of bid documents, which it receives not later than date mentioned in critical date sheet and prior to the prebid meeting. Queries received after the pre-bid date mentioned in the critical date sheet will not be entertained.
- ii) The Tenderers or their Official Representatives are invited to attend a pre-bid meeting which will take place as specified in critical date sheet.
- iii) Any clarification issued by CMSS in response to query raised by prospective bidders shall form an integral part of bid documents and it may amount to an amendment of the relevant clauses of the bid documents.
- iv) The clarification if any will be uploaded at CPPP and on eprocurement website and bidder is expected to see the CMSS website for clarification before submitting the bid.

4. ELIGIBILITY CRITERIA

- (a) Only Class- 1 local supplier and class- II local supplier shall be eligible for participation. Bids from supplier (MSE/Non MSE) as defined in Department of Pharmaceuticals under Ministry of Chemicals and Fertilizers order no F. No 31026/65/2020-MD dated 30.12.2020 shall be accepted. Bids from firms/vendors other than Class- 1 and class- II local supplier (MSE/Non MSE) shall be summarily rejected.
- (b) Tenderer shall be a manufacturer of the quoted product and have a valid own manufacturing license (For Domestic) in the indicated pharmacopeia (in the technical specification at Annexure IA) and Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any of the pharmacopeia IP/BP/USP/IHS. The manufacturing license & COPP should be valid on the date of tender opening packet 1.
- (c) For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCG (I) less than two years ago. DCG(I) is permission shall be required for all new regulated products to this effect.

Schedule	Amount (in Rs.) for 100% quantity
1	3 Lakh
Ш	3 Lakh
	2 Lakh
IV	1 Lakh
V	50 Thousand
VI	15 Lakh
VII	6 Lakh
VIII	4 Lakh

(d) Average Annual turnover for Tenderers in the last three years i.e. 2019-20, 2020-21 and 2021-2022 shall not be less than the following:

IX	3 Lakh
X	2 Lakh

The turnover benchmark will not apply to Micro and Small Enterprises (MSE).

e) Department of Expenditure, Ministry of Finance, GOI vide OM No: F.1/20/2018/PPD dtd. 02.11.2021 has issued guidelines on debarment of firms from bidding. The bidders blacklisted by any firm/company/ CMSS /State Govt. /Central Govt./its drug procuring agencies prior to issuance of DOE OM No: F.1/20/2018/PPD dtd. 02.11.2021 are eligible to bid if:- The blacklisting order has been revised post facto with clearly mentioning of category (i) of OM No: F.1/20/2018/PPD dtd. 02.11.2021 and that the debarment is limited to the issuing ministry/department/ organization only. Such vendors should clearly mention the status of blacklisting in the undertaking to be submitted in compliance with clause 6.1 (t) of tender documents and also attach revised blacklisting order.

For blacklisting orders issued after 02.11.2021, the following shall be applicable: -

- If the blacklisting order is issued by DoE, the bid of blacklisted bidder shall be out rightly rejected.
- If the blacklisting order is issued by CPSUs, attached offices/autonomous bodies etc of MoHFW/ Other Ministries/ department and MoHFW/ Other Ministries/ department by written approval has delegated powers under Sr. no. (8) of OM dated 02.11.2021 to such organizations /bodies that the blacklisting is applicable only for the Procurement made by such organization /bodies, the bid of such blacklisted bidders shall be accepted for further evaluation.
- In absence of such delegation extended by MoHFW/ Other Ministries/ department, the bid of the blacklisted bidder shall be rejected.
- f) Tenderer should quote for 100% of the tendered quantity of each items quoted and the Tenderer shall have an annual production capacity not less than one and half times the quantity quoted for each schedule.

g) Tenderer should have supplied 40% of the quoted quantity of same or similar items during the last two financial years. Bidder should submit Purchase order copies (issued in the last two Financial Years) and certificate duly issued by statutory auditor of the company on his letter head by certifying the quantities manufactured and marketed in trade, export, open market, sold to government institutions, private bodies etc. and the marketed quantities are not less than at least 40% of the quoted/similar item. Similar item is defined as below:

For Sch I & II - Any drugs of Vector Borne Disease

Supply/Sale/Service under loan license arrangement shall not be considered.

5. GENERAL CONDITIONS

- A complete set of tender document may be downloaded by any interested eligible bidder from website: <u>https://eprocure.gov.in/eprocure/app</u> as per the schedule given in Critical Date Sheet. No cost for the Tender document shall be charged for the Tender documents downloaded by the Tenderers.
- (ii) All tenders must be accompanied with Earnest Money Deposit as specified against each schedule in **Annexure-III** of the Tender document.
- (iii) Tenders will be opened online therefore, the presence of tenderers/authorized representatives of the Tenderers is not necessary.
- (iv) Bidders are advised to watch for amendments, if any, which may be issued prior date of submission of bids by tender inviting authority on the website: <u>www.cmss.gov.in</u> and https://eprocure.gov.in/eprocure/app for which CMSS will not issue any separate communication to individual bidders.
- (v) All notices or communications relating to and arising out of this tender and any consequent agreement or any of the terms thereof shall be considered duly served on or given to the Tenderer if

delivered to it or left at the premises, places of business or abode or sent at official email as provided by the Tenderer.

(vi) FORGERY/FRAUD BY BIDDERS/SUPPLIER :

Genuineness of the papers/documents/certificates/ declaration submitted with bid is the responsibility of the bidder. Also the bidder should take utmost care in submitting undertakings/self declaration/certificates along with its bid. If at any stage it is found documents/ certificates/ that the papers/ declaration/ undertaking/ self certification submitted by the bidder are false/incorrect/suppressed/ misrepresented the actual fact or are not in order, are forged, manipulated, fabricated or altered, the bid or purchase order issued to the bidder is liable to be cancelled and further necessary action including forfeiture of its EMD/Security Deposit, debarring/blacklisting against the bidder will be taken. Purchaser may also initiate police/legal action and request concerned statutory authority for cancellation of license issued to supplier for tendered items.

- (a) If any fraud, short supply of goods is detected on part of the bidder at any stage, the bid or work order/Purchase order issued to the bidder is liable to be cancelled and further necessary action against the bidder including debarring/blacklisting will be taken.
- (b) In any of above two cases, the CMSS is at liberty to make alternative purchase of the tendered items from other approved suppliers or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier.

(vii) **PATENT RIGHTS:**

The supplier shall indemnify the purchaser against all third-party claims of infringement of patent, trademark or industrial design rights arising from use of the goods or any part thereof.

In event of any such claim in respect of alleged breach of patent, registered designs, trademarks etc. being made against TIA, the TIA shall notify the supplier of the same and the supplier shall at its own expenses take care of the same for settlement without any liability to the TIA.

(viii) **TERMINATION FOR DEFAULT**:

- 1. The purchaser may, without prejudice to any other remedy for breach of contract, by written notice of default, sent to the supplier, terminate this contract in whole or in part.
 - (a) If the supplier fails to deliver any or all of the goods within the time period(s) specified in the contract, or any extension thereof granted by the purchaser.
 - (b) If the supplier fails to perform any other obligation(s) under the contract, and
 - (c) If the supplier, in either of the above circumstances, does not remedy his failure within a period of 15 days (or such longer period as the purchaser may authorize in writing) after receipt of the default notice from the purchaser.
- 2. In the event the purchaser terminates the contract in whole or in part, pursuant to above the purchaser may procure; upon such terms and in such manner, as it deems appropriate, tendered goods undelivered and the supplier shall be liable to the purchaser for any excess cost for such similar goods. However, the supplier shall continue performance of the contract to the extent not terminated.

(ix) **TERMINATION FOR INSOLVENCY:**

The purchaser may, at any time, terminate the contract by giving written notice to the supplier, without compensation to the supplier, if the supplier becomes bankrupt or otherwise insolvent, as declared by the competent court provided that such, termination will not prejudice or affect any right of action or remedy which has accrued or will accrue thereafter to the purchaser.

(x) SET OFF:

Any sum of money due and payable to the supplier (including security deposit refundable to him) under this contract may be appropriated by the purchaser and set off the same against any claim of the purchaser for payment of a sum of money arising out of this contract or under any other contract made by the supplier with the Purchaser.

(xi) Purchaser reserves the right to debar/ blacklist a bidder for a suitable period in case he fails to honour his bid/contract without sufficient grounds.

(xii) **BID SUBMISSION:**

- (a) Bidders are hereby cautioned that any attempt of cartel formation will be viewed seriously and may at the discretion of purchaser, lead to cancellation of tender. Purchaser in its discretion may decide to forfeit EMD of such bidders and black list or debar these bidders for suitable period besides taking other punitive measures. Decision of purchaser in this regard shall be final and binding.
- (b) (i) Different firms or companies having any common partner(s) or Director(s) or representative not permitted to quote for more than one tender offer. In case more than one offer is received from such bidders, then all such offers except with the lowest quote shall be rejected summarily.
- (ii) In case more than one offer for any tendered item is received from the same bidder, then all such offers except with the lowest quote shall be rejected summarily.

(xiii) NEAR RELATIVE CERTIFICATE:

The bidder should give a certificate that none of his/her near relative as defined below is working in CMSS where he is going to apply for the tender. In case of Proprietorship firm certificate will be given by the proprietor. For partnership firm certificate will be given by all the partners and in case of limited company by all the Directors of the company excluding Govt. of India/Financial Institutions nominees and independent non-official part time directors appointed by Govt. of India or the Governor of the state. Authorised signatory of bid may also sign this bid on behalf of the entire directors/ partners/ proprietor. Due to any breach of conditions by the company or firm or any other person the tender will be cancelled and bid security will be forfeited at any stage whenever it is noticed and CMSS will not pay any damage to the company or firm or the concerned person. The company or firm or the person will also be debarred for further participation for quoted item in the concerned unit.

The near relatives for this purpose are defined as:

- (a) Members of a Hindu undivided family.
- (b) They are husband and wife.
- (c) The one is related to the other in the manner as father, mother, son(s) & son's wife (Daughter in law), daughter(s) and daughter's husband (son in law), brothers(s) and brother's wife, sister(s) and sister's husband (brother in law).

An undertaking as specified in Annexure XVIII is to be submitted.

6. TECHNICAL BID – "PACKET1"

Those intending to participate in the tender (herein called Tenderer) should first ensure that they fulfil all the eligibility criteria and **all documents should be valid on the date of tender opening packet 1**:

- 6.1 The Tenderer should electronically submit the soft copies of following documents in Technical Bid "Packet 1". (All the documents submitted should bear signature and stamp of the Tenderer)."
- (a) DD/FDR/RTGS/NEFT e-receipt or Bank Guarantee (if applicable) in respect of EMD as per Clause 9 of this Tender document or in case of MSE, a copy of their valid registration certificate in support of their being an MSE and a notarised undertaking given in Annexure VIII.
- (b) Tender Forwarding letter as per Annexure-II.
- (c) The Tenderer should furnish the Manufacturing License (For domestic in form of 25 or 28 issued from State Licensing Authority) valid on tender opening for each item quoted been duly renewed up to

date and the items quoted shall be clearly highlighted in the license. Original documents should be produced for verification when demanded. If the tendered drug is in Indian Pharmacopoeia (IP), then the manufacturing license has to be submitted in IP only.

For drugs that are not available in IP, other official Pharmacopeia (s) are applicable. If a drug is not available in any of the official pharmacopeias, 'In House' standards are applicable as per the Drugs and Cosmetics Act 1940 and the Rules there.

Bidder is requested to submit an undertaking that the drug is not available in IP or any other approved pharmacopeia.

- (d) Duly notarized general power of Attorney (on non-judicial stamp paper of worth Rs. 50/- or above) in favour of authorized signatory in case of partnership firm (to be signed by all partners) / proprietorship firm or board resolution in case of a company to sign the bid and bind the bidder. The signature of authorized signatory should be duly attested. In case of proprietorship on its letter head, the proprietor of firm declares himself as proprietor with specimen signature.
- (e) Manufacturing and Market Standing Certificate / Market Standing Certificate issued by the Licensing Authority as a manufacturer for each item quoted for the last 2 years i.e 2020-21 & 2021-22 for compliance of tender clause 4.c.
 - (f) A valid Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any pharmacopeia IP/BP/USP and a valid WHO-GMP.
 - (g) Capacity certificate issued by the licensing authority.

- (h) Tenderer should have supplied 40% of quoted or similar item (as per clause 4g) during the last 2 financial years (Copies of P.O's to be submitted along with Statutory Auditor certificate). Similar items are defined at 4 (g).
- (i) Non-Conviction Certificate issued by the FDA/ Drugs Controller of the State certifying that the firm/company has not been convicted and the products quoted have not been cancelled during last two years i.e. 2020-2021 and 2021-2022.
- (j) Annual turnover statement for 3 years i.e. 2019-20, 2020-2021 and 2021-2022 should be furnished in the format given in Annexure-V duly certified by the Chartered Accountant.
- (k) Copies of the audited Annual reports including Balance Sheet and Profit and Loss Account along with all the annexure for the last three years i.e. 2019-20, 2020-2021 and 2021-2022 duly certified by a practicing Chartered Accountant.
 - List of items quoted (the name and Item Code of the items quoted) and relevant pharmacopoeia annual production for the last 2 years as per the Annexure-VI.
- (m) Long Term (Real Time) Stability Data of the quoted product in specified packing for at least for 3 batches, to support shelf life.
- (n) A Checklist (Annexure-VII) indicating the documents submitted with the tender document and their respective page numbers shall be enclosed with the tender document. The documents should be serially arranged.

- (o) Each page of submitted bid (along with tender document) be properly page numbered and shall be signed by the authorized signatory of the Tenderer with office seal.
- (p) All the documents enclosed with the tender document should also be signed by the authorized signatory of the Tenderer.
- (q) No Deviation Certificate as per Annexure-XVII.
- (r) Near Relative Certificate as per Annexure -XVIII.
- (s) Draft artwork is to be submitted in technical bid.
- (†) Tenderer should submit an undertaking that "I/ We do hereby declare that our firm has not been blacklisted/ banned/debarred by CMSS/ State Governments/ Central Government/ MOH&FW or any of the procurement agencies/ Autonomous Bodies under the organizations stated above or the Firm/ Company (as whole) has not been debarred as a whole by these organizations or any of its procurement agencies/ Autonomous Bodies"
- (u) Tenderer should submit a certificate from the statutory auditor or cost auditor of the company (in the case of companies) or from a practicing cost accountant or practicing chartered accountant (in respect of suppliers other than companies) giving the percentage of local content as per clause 10.4 of this tender at the time of submission of bid. As per Annexure XIX.
- (v) Vendors are requested to fulfil the requirements of Ministry of Finance, Department of Expenditure, Procurement Policy Division Office Memorandum No.- 6/9/2020-PPD dated 24.08.2020.

- (w) Tenderer should submit an Undertaking on Letter head to Compliance to Ministry of Finance, DOE order No- 6/18/2019-PPD dated 23.07.2020 as per Annexure-XX.
- (x) Performa for performance Statement as per Annexure-IV.
- (y) Mandate form for RTGS as per Annexure-XII
- 6.2 The above mentioned documents are to be submitted in soft copy electronically on the CPPP portal <u>https://eprocure.gov.in/eprocure/app</u> as Technical Bid "Packet 1" as per date prescribed in critical date sheet and as per instructions of online bid submission given in **Annexure-XVI**.
 - (a) All original document in lieu of EMD / Notarised undertaking by MSE companies Annexure VIII for Exemption of EMD in physical form is to be deposited with the Tender Inviting Authority upto bid submission end date and time as per prescribed in the critical date sheet. If the last date of deposit of original Bank Guarantee/Notarised undertaking by MSE companies Annexure VIII for Exemption of EMD happens to be a central government holiday for offices located in New Delhi, next working day shall be treated as the last date of deposit. The original Bank Guarantee/Notarised undertaking by MSE companies Annexure VIII for Exemption of EMD may be either deposited in person or by courier. If sent by courier, the tenderer has to send it in advance so as to make sure that the original Bank Guarantee/Notarised undertaking by MSE companies Annexure VIII for Exemption of EMD is delivered to the Tender Inviting Authority by the date specified in critical date sheet. Failure to deposit the All original document in lieu of EMD /Notarised undertaking by MSE companies Annexure VIII for Exemption of EMD by the specified last date shall result in rejection of bid summarily.
 - (b) Conditional Bids shall be summarily rejected.

7. <u>PRICE BID-"Packet 2"</u>

- 7.1 "Packet 2" is for the Price Bid of the Tenderer.
 - i) Bid should be uploaded online in the form of BOQ.XXXX.xls.
 - ii) Format of the Schedules of price bid is available in Annexure-XIII.
 - iii) The supplier shall quote as per price schedule given in Annexure-XIII for all the items quoted by him as per schedule of requirement.
 - iv) The price quoted shall be the landed price per unit at the specified locations on DDP basis and shall include all taxes and duties including transportation and other incidental expenditure for delivery at CMSS warehouses.
 - v) The rate quoted in Price Schedule Annexure-XIII should be for a unit as given in specifications as detailed in the tender document. The bidder is not permitted to change / alter specification or unit size in the box.

7.2 GST (Goods and Service Tax)/other statutory Taxes/Levies

- i) The bidder may quote for GST as per applicability in accordance with relevant Government notification.
- ii) Any variation upwards/downwards as a result of statutory variation in GST/ other taxes/duties/levies for supplies during original specified delivery schedule of goods shall be allowed.

- iii) Any upward/downward revision (only during scheduled delivery period) in statutory taxes, levies will be allowed and benefit will pass on to supplier/purchaser.
- iv) Any increase in taxes and other statutory duties/levies after the expiry of the delivery date shall be to the supplier's accounts. However, the benefit of any decrease in these taxes/duties shall be passed on to the purchaser by the supplier.
- 7.3 The basic unit price quoted by the bidder shall remain fixed during the entire period of contract and shall not be subject to variation on any account. A bid submitted with an adjustable price quotation will be treated as non-responsive and rejected.

8. OPENING OF "PACKET 1"i.e. 'TECHNICAL BID AND "PACKET 2" i.e. FINANCIAL BID' OF TENDER CLARIFICATION OF BIDS SUBMITTED:

- 8.1 To assist in the examination, evaluation and comparison of bids, the purchaser may, at his discretion ask the bidder for the clarification in its bid. The request for the clarification and response shall be in writing. However, no post bid clarification at the initiative of the bidder shall be entertained. Documents issued after the date of tender opening will not be accepted.
- 8.2 Tenderers are advised to submit all the required documents as per tender terms and conditions. Failure to submit shall result in rejection of bids. Clarifications (if required) to assist in the evaluation of bids will be asked by the purchaser only once. The tenderer is requested to reply in the given time by purchaser.

- 8.3 Presence of authorized official of the Tenderer is not necessary at the time of opening of Technical Bid - "Packet 1" as opening is online.
- 8.4 The purchaser shall evaluate the bids to determine whether they are complete, whether any computational errors have been made, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are generally in order.
- 8.5 Prior to the detailed evaluation, pursuant to clause above, the purchaser will determine the substantial responsiveness of each bid to the bid documents for purposes of these clauses. A substantially responsive bid is one, which confirms to all the terms and conditions of the bid documents without material deviations. The purchaser's determination of bid's responsiveness shall be based on the contents of the bid itself without recourse to extrinsic evidence.
- 8.6 A bid determined as substantially non-responsive will be rejected by the purchaser and shall not subsequent to the bid opening be made responsive by the bidder by correction of the nonconformity.
- 8.7 The purchaser may waive any minor infirmity or non-conformity or irregularity in a bid, which does not constitute a material deviation, provided such waiver does not prejudice or affect the relative ranking of any bidder. Such minor infirmity will be identified by the TEC and clarification in this regard may be called for.
- 8.8 Technical Evaluation Summary will be uploaded on CPPP Portal. The bidders are intimated that representations, if any, may be sent

before price bid opening as per schedule indicated in uploaded summary. Any representations received after the indicated date and time would not be entertained **under any circumstances.** No new document would be allowed to be submitted at this stage.

- 8.9 "Packet 2" will be opened only for tenderers, who are found techno-commercially eligible on satisfying the criteria for technical evaluation and plant inspection (wherever necessary) based on the documents submitted in "Packet 1". Presence of authorized official of Tenderers is not necessary in opening of "Packet 2" as opening is online.
- 8.10 Arithmetical errors shall be rectified on the following basis. If there is a discrepancy between the unit price and total price that is obtained multiplying the unit price and quantity, the unit price shall prevail and total price shall be corrected by the purchaser. If there is a discrepancy between words and figures, the amount in words shall prevail.

9. EARNEST MONEY DEPOSIT

9.1. (a)The Earnest Money Deposit (EMD) is payable by all Tenderers, for an amount indicated in Annexure-III UNLESS EXEMPTED under clause 9.2. In case a Tenderer is quoting for more than one item, the Earnest Money Deposit payable by such Tenderer shall be the aggregate total of the Earnest Money Deposit for all the items quoted by such Tenderer. The Tenderers are required to furnish the breakup of the Earnest Money Deposit for the items quoted in the format as per Annexure-III. The Earnest Money Deposit shall be paid by Account payee/ Demand Draft/ Fixed Deposit Receipt/ Banker's Cheque /Bank Guarantee or RTGS/NEFT/Insurance Surety Bonds in the following Bank Account: Beneficiary Name: Central Medical Services Society A/C No. : 32719062216 Bank Name: SBI Bank Branch: Nirman Bhawan, Maulana Azad Road, New Delhi IFSC Code: SBIN0000583

(b) Bank Guarantee (as per Annexure XIV) can also be accepted as a mode of payment and the named beneficiary shall be Central Medical Services Society. The Bank guarantee shall be issued by a bank (Nationalized or Scheduled Bank) in India to make it enforceable and acceptable to the purchaser. The Bank Guarantee shall be in the format as per Annex-XIV provided in the tender document.

EMD shall remain valid for 45 days beyond the validity period for the bid and will be extended accordingly beyond any extension subsequently requested by purchaser.

(c)The applicable EMD amount has been indicated in Annexure-III and is for 100% and 50% quantity of the schedule. If quoted quantity is anywhere between **50%** to **100%** of the quantity of schedule, the applicable EMD may be calculated by the tenderer by proportionately reducing the amount applicable to 100% quantity.

9.2 EXEMPTION FROM PAYMENT OF EARNEST MONEY DEPOSIT TO MSME (MICRO & SMALL ENTERPRISES)

(i) (The MSE Units will be required to furnish a notarized undertaking (as per **Annexure-VIII**) to the effect that in the event of non-fulfillment or non-observance of any of the conditions stipulated in the tender, the MSE Unit shall pay a penalty, equivalent to the Earnest Money Deposit to offset the loss incurred by the Tender Inviting Authority consequent on such breach of any bid condition.

- (ii) Vide Gazette no. CG-DL-E-26062020-220191 dt. 26.06.2020, Ministry of MSME have revised criteria for classifying the enterprises as Micro, small and Medium enterprises with effect from 1st July 2020 therefore following firms will be exempted from submission of EMD.
 - a) Micro and Small Enterprises as per classification given in MSME Notification dtd. 26.06.2020 registered under "Udyam Registration" w.e.f 01.07.2020 will be granted exemption from payment of Earnest Money Deposit. Udyam Registration Certificate has to be produced in support of above.

Note: Traders will not get benefit of MSE Firms

- **9.3.**(i) Offers of the firms submitted without EMD / for a shorter period/lesser amount as demanded will summarily rejected. (if applicable)
 - (ii) The Earnest Money Deposit will be refunded to the lowest responsive bidder/s within 30 days from the date of signing the contract agreement and on the deposit of Security Deposit.
 - (iii) The Earnest Money Deposit (EMD) furnished by all unsuccessful tenderers will be returned as early as possible after the expiration of the period of tender validity but not later than 30 days of the award of the contract.

9.4 FORFEITURE OF EMD (if applicable)

- (i) The Earnest Money Deposit (EMD) will be forfeited/vendor would be required to deposit the equivalent EMD amount as per Notarised Undertaking by MSE bidder, if the Tenderer withdraws or amends, impairs or derogates from the tender in any respect within the period of validity of his Tender.
- (ii) The Earnest Money Deposit (EMD) will be forfeited/ vendor would be required to deposit the equivalent EMD amount as per Notarised Undertaking by MSE bidder, in case of the lowest/ matched bidder, fails to execute the contract agreement and / or deposit the Security Deposit within the stipulated time. Additionally, actions as stipulated in clause no. 18.1 will also be taken.

(iii) In both the above cases, the bidder will not be eligible to participate in the tender for same item for two years from the date of issue of letter of acceptance. The bidder will not approach the court against the decision of the CMSS in this regard.

10. OTHER CONDITIONS:

- 10.1 The details of the annual required quantity of *items* are shown in **Annexure-I**
 - (i) Central Medical Services Society (CMSS) will have the right to increase or decrease up to 25% of the quantity of goods and/or services specified in the schedule of requirements without any change in the unit price or other terms and conditions at the time of award of contract.
 - (ii) In exceptional situation where the requirement is of an emergent nature and/ or it is necessary to ensure continued supplies from the existing vendors, the purchaser reserves the right to place repeat order up to 50% of the quantity of the goods and/or services contained in the running tender/contract up to a period of twelve months from the earliest date of Long Term agreement (LTA) at the same rate or a rate negotiated (downwardly) with the existing vendors considering the reasonability of rates based on prevailing market conditions and the impact of reduction in duties and taxes etc.
 - (iii) The delivery of the additional quantity (as per ii above) shall be scheduled after the completion of the delivery of the original tendered quantity or on mutual consent between the supplier and CMSS.
- 10.2 (i) The rates quoted and accepted will be binding on the Tenderer for the full contract period of **ONE year** and any increase in the price will not be entertained till the completion of this contract period.
 - (ii) Any upward/downward revision (only during scheduled delivery period) in statutory taxes, levies will be allowed and benefit will pass on to supplier/purchaser.

- (iii) Any increase in taxes and other statutory duties/levies after the expiry of the delivery date shall be to the supplier's accounts. However, the benefit of any decrease in these taxes/duties shall be passed on to the purchaser by the supplier.
- (iv) The delivery of the additional quantity shall be scheduled after the completion of the delivery of the original tendered quantity.
- In accordance to the notification the participating Micro and Small 10.3 Enterprises (MSEs) in a tender, quoting price within the band of L1 + 15% would be allowed to supply a portion of the requirement by bringing down their price to the L 1 price, in a situation where L 1 price is from someone other than an MSE. In exercising of the powers conferred in Section 11 of the Micro, Small and Medium Enterprises Development (MSMED) Act 2006, the Government has notified a new Public Procurement Policy for Micro & Small Enterprises effective from 9th November 2018. The policy mandates that 25% of procurement of annual requirement of goods and services by all Central Ministries / Public Sector Undertakings will be from the Micro and Small Enterprises. Government has also earmarked a sub target of 4% procurement of goods & services out of 25% from MSEs owned by SC/ST entrepreneurs and 3% to micro and small enterprises owned by women.
- 10.4 The Department of Pharmaceuticals under Ministry of Chemicals and Fertilizers has issued guidelines for implementation of the provisions of public procurement (Preference to Make in India) order (PPO) 2017 revision related to procurement of goods and services in Pharmaceuticals formulations vide order no F.No 31026/65/2020-MD dated 30.12.2020. The relevant provisions of DoP order dt. 30.12.2021 and DPIIT order dt. 16.09.2020 and all subsequent orders from time to time will apply in the instant case. Bidders are requested to submit a declaration indicating percentage of local content as per Annexure XIX.

11. ACCEPTANCE OF TENDER

- 11.1 Technically responsive tenders will be evaluated based only on the "landed price" (all-inclusive price), i.e. Rate per Unit inclusive of all taxes, duties, transportation& other charges.
- 11.2 The evaluation for ranking shall be carried out on the basis of "all

inclusive" prices of the goods offered for each schedule separately.

- 11.3 The purchaser reserves the right to accept or reject any bid, and to annul the bidding process and reject all bids, at any time prior to award of contract without assigning any reason whatsoever and without thereby incurring any liability to the affected bidder or bidders on the grounds of purchaser's action.
- 11.4 (i) CMSS or its authorized representative(s) has the right to inspect the factories of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/ cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections. In such situation CMSS reserves the right to take other actions against the tenderer including forfeit of security deposit, debarring/blacklisting for appropriate period.
 - (ii) The Tenderer shall allow inspection of the factory at any time by a team of Experts/ Officials nominated by the Tender Inviting Authority for the purpose. The Tenderer shall extend necessary cooperation to such team in inspection of the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If Company/ Firm does not allow for any such inspection, their tenders will be rejected during the currency of the contract.
- 11.5 The acceptance of the tenders will be communicated to the lowest / matched tenderers in writing (through email), as per format of the Acceptance Letter given in **Annexure-IX.**

12. SECURITY DEPOSIT ANDAGREEMENT

12.1 Security Deposit:

In accordance with Department of Expenditure Ministry of Finance notification dated 12.11.2020, the clause may be read as:

On being intimated about the acceptance of the tender the L1/Matched tenderer shall pay a Security Deposit at the rate of 3% of the total value of goods to be awarded. The Security Deposit amount, is to be deposited in the form of NEFT/RTGS/Fixed Deposit Receipt/Demand Draft (payable at New Delhi)/Bank Guarantee in favor of Central Medical Service Society.

Beneficiary Name: Central Medical Services Society A/C No. 32719062216

Bank Name: SBIBank Branch: Nirman Bhawan, Maulana Azad Road, New Delhi IFSC Code: SBIN0000583

12.2 The Performance Bank Guarantee shall be valid for at least 500+ 365x (shelf Life year) day from the date of commencement.

LOA Submission	-15 days
Rate Valid	-365 days
Delivery period	- 90 days
Shelf life	-365 x (shelf Life year)
B.G. Extension	- <u>60 days</u>
	530+ 365x (shelf Life year)

- 12.3 The lowest/ matched tenderer shall execute an Agreement on a nonjudicial stamp paper of value of Rs.100/- (stamp duty to be paid by the Tenderer) within 15 days from the date of the intimation from CMSS informing that his tender has been accepted. The Specimen form of Agreement is available in **Annexure-X**.
- 12.4 The proceeds of the performance security shall be payable to the purchaser as compensation for any loss resulting from the supplier's failure to complete its obligations under the contract.
- 12.5 The performance security bond will be discharged by the purchaser after completion of the supplier's performance obligations including any warranty obligations under the contract.
- 12.6 Failure to deposit the performance security will attract clause 9.4.

13. METHODOLOGY FOR PLACING ORDERS

For placing orders the following procedures will be adopted:

- 13.1 After the Price Bid opening, the lowest offer will be declared as the L1 tenderer. CMSS reserves right to negotiate prices with L1 bidder in justified cases.
- 13.2 The Tenderer, who has been declared as Lowest Tenderer for certain item(s), shall within the tender issue of LOA (letter of acceptance) execute necessary Agreement for the supply of the allocated quantity of such items as specified in the Tender Document after depositing the required amount as Security Deposit and on execution of the agreement such

Tenderer shall supply goods on receipt of Purchase Orders. The format of LOA, agreement, Purchase Order is attached at **Annexure -IX, X, XI** respectively. Generally speaking the draft art work should be given in technical specifications however, in those cases where draft artwork not given in tender specifications, the vendor must need to coordinate with respective programme division of ministry to freeze (get approval) for the art work. No extension would be given on this pretext.

- 13.3 If two or more than two Tenderers are declared as lowest suppliers for the same item(s) (i.e. emerge L1), such Tenderers shall execute necessary agreement as specified in the Tender Document on depositing the required amount as Security Deposit and on execution of the agreement such Tenderer will be eligible for placement of Purchase Orders for equal proportion of tendered quantities (50:50 or 33.33:33.33:33.33) for such item(s) for which they are declared as lowest (L1).
- 13.4 CMSS will counter offer the lowest rate (L1 rate) to other Tenderers in the order of their ranking i.e. L2, L3 and so on will be asked to match the L1 price-Not Applicable.
- 13.5 CMSS will counter offer the lowest rate (L1 rate) to other Tenderers in the order of their ranking i.e. L2, L3 and so on will be asked to match the L1 price Not Applicable.
 - i. In order to maintain uninterrupted supplies, the CMSS will place orders with minimum of two suppliers for tendered product with 70% of the orders given to L1 and the balance 30% to the next Matched Lowest Tenderer.
 - ii. In case there is no L2 /matched bidder, balance quantity up to extent of quoted quantity or at most for balance 50% quantity can be offered to L1 bidder. Quantity beyond quoted quantity will be ordered on mutual consent.
 - iii. In case, L2 bidder/matched bidder refuses to accept the offered quantity, balance quantity up to extent of quoted quantity or at most for balance 50% quantity can be offered to L1 bidder. Quantity beyond quoted quantity (and including quantity in consideration in Clause No. 10.1 (i)) will be ordered on mutual consent.

- iv. In case L1 bidder has quoted for 50% quantity, the balance quantity will be offered to L2 and L3 bidders for 30% and 20% quantity respectively.
- v. In case there is no L3/matched bidder at 3rd position (i) above may be followed or balance 50% quantity may be offered to L2/matched bidder in case L1 does not agree to supply 70% of tendered quantity.
- vi. In case of requirement of large quantities, CMSS may place orders with 3 suppliers in the ratio of 50:30:20, which will be indicated in the tender document at **Annexure-I**.
- 13.6 If the lowest supplier has failed to supply the required items within the stipulated time or within the extended time, as the case may be, CMSS may cancel such purchase orders and on cancellation, CMSS *may* place Purchase Orders with the Matched Lowest Tenderer or to the other tenderers at the risk and cost of the defaulted supplier.
- 13.7 The supplier shall complete the supply of the items required by CMSS at the consignee destination mentioned in the schedule, within minimum required period as stipulated in order from the date of the orders.
- 13.8 The supplier shall supply the items at the specified destination and submit a copy of the Purchase Order, Delivery Challan and other relevant documents at the same destinations.
- 13.9 After supply of items at the specified destinations, the supplier shall submit Invoice (Original), Certificate of analysis (Batch Wise) and other relevant documents etc., at the Head Office, CMSS for claiming payment.
- 13.10 Subject to para (13.6) to para (13.9) above, CMSS will process the invoices submitted by the supplier and the payments against supply will be made within 60 days from the date of submission of all relevant documents to the CMSS provided the items supplied has been declared of STANDARD QUALITY, by the Empanelled Laboratory of CMSS.

14 SUPPLY / DELIVERY CONDITIONS

14.1 The supplier should acknowledge the receipt of the Purchase Order within 3 days of its receipt

- 14.2 The supplies will be made in staggered quantities (if applicable) as detailed in **Annexure-I**.
- 14.3(a) The supplier shall supply the ordered quantity within minimum required period of 90 days (or as mentioned in LOA/PO) from the date of award at the destinations mentioned. If the above day happened to be a holiday for CMSS, the supply should be completed by 5.00 PM on the next working day. In case of non-execution of the order either partially or fully, CMSS reserves the right to cancel the purchase order or place fresh purchase orders on alternative source at the risk and cost of the default supplier. In such cases the CMSS, has every right to recover the cost and impose penalty including blacklisting of the supplier and the product.
 - (b) With the prior approval of CMSS, the supplier may continue to supply the unexecuted quantity after 90th day or after the delivery dates/schedule as mentioned in order with Liquidated Damages as specified in Clause 18 of the tender conditions on the delayed supplies.
 - (c) Supplies should be made directly by the tenderer and not through any other Agency/Dealer/Distributor.
 - (d) The Tenderer shall not, at any time, assign, or make over the contract or the benefit there of or any part thereof to any person or persons whatsoever.

14.4 All goods must be of fresh manufacturing and must bear the dates of manufacturing and expiry. The bidder further warrants that all goods supplied will have, at least 5/6th of the minimum shelf life must remain at the time of delivery to the consignee. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.

14.5 For both items delivered to direct consignees & CMSS warehouses, the supplier should ensure that the items are delivered with the minimum shelf-life as mentioned in the tender document/Purchase Order failing which the consignees/CMSS WHs shall not accept the items. Further, the bidder's attention is invited that if they supply/deliver the items with short shelf-life as per tender/Purchase Order and even if direct consignees receive such items, the invoices shall not be processed by CMSS for payments. It is the sole responsibility of the bidder/vendor to deliver the items with minimum residual shelf-life as mentioned in the tender/Purchase Order.

14.6 A Certificate of Analysis/ Performance Evaluation Report from manufacturer's own Quality Control Lab covering each batch delivered is to be submitted along with shipping documents.

The Certificate of Analysis shall include:

- a) Generic name of the product
- b) Batch No.
- c) Pharmacopoeial Reference and/ or In-house method
- d) Batch quantity
- e) Date of manufacture
- f) Expiry date
- g) Date of test
- h) Description
- i) All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
- j) Conclusion
- k) Qualified signatures

as applicable

OR/And

The Performance Evaluation Report shall include:

- a) Product name
- b) Lot/Batch Number
- c) Date of manufacture
- d) Date of Expiry
- e) Manufacturer's name
- f) Number of samples tested
- g) Testing principle

Information about reference used

- h) TESTING PROCEDURE- Sensitivity, Specificity etc
- i) Results
- j) report number
- k) Date of Analysis
- I) Designation and signature of analyst
- m) Authorized signatory of lab

The above mentioned batch shall be manufactured in accordance with the applicable GMP/QMS regulations.

- 14.7 All the Tenderers are required to supply the product(s) with printed text "NVBDCP SUPPLIES – NOT FOR SALE" in red-colour on the strips, blisters, vials, ampoules & bottles and also on the external packings. The type/thickness of packing materials used in Blister packs may also be specified. Goods received without this print will not be accepted by CMSS/Consignee. Affixing of rubber stamp shall not be accepted. However, the approved art work will prevail.
- 14.8 If at any time the Tenderer has, in the opinion of the CMSS, delayed the supply of items due to one or more reasons related to Force Majeure events such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the items may be extended by the CMSS at its discretion for such period as may be considered reasonable. However, such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event. The exceptional events do not include scarcity of raw material, increase in the cost of raw material, electricity failure, labour disputes/ strikes, insolvency, and closure of the factory/ manufacturing unit on any grounds etc.
- 14.9 The supplier shall not be liable to pay LD/ penalty and forfeiture of security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

15. PACKING

- 15.1 The items shall be supplied in the package specified in the Technical Specifications in **Annexure-I.**
- 15.2 The Weight, Volume & Dimensions of shipping cartons & intermediate packaging carton may be mentioned.
- 15.3 The packing shall be of a sturdy quality to provide adequate protection of the product for carriage to final destination, **PAN INDIA** including remote locations under adverse climatic and storage conditions and high humidity. Used cartons should never be used.
- 15.4 Products with specific temperature requirements will be packed and stored and delivered in appropriate conditions.
- 15.5 The packaging unit should be strong, able to be stacked to a height of 4

pallets as static storage and 2 pallets during transport, and resistant to puncturing.

15.6 Special attention of suppliers is invited to ensure the material is of good quality and is free from development of fungus/termites. In case fungus/termites develops within 15 days of delivery at specified locations, suppliers at their own cost would lift the entire batch from various locations and supply fresh replaced batches. For LD purposes the date of receipt of replaced batches would count. In addition, the expenses on pest control to be undertaken by CMSS would be borne by the tenderer.

16. QUALITYCONTROL

- 16.1 Quality Control is an essential part of the current procurement and it is the responsibility of the supplier to ensure quality assurance as per specifications/bid document. The products should conform to the standards as specified in Annexure-I of the Tender document.
- 16.2 The bidder/supplier understand that the tender editem /items/ are critical health goods and the quality parameters of supplied goods are to be ensured during complete specified shelf life as indicated in technical specification/bid document/official compendium. Bidder/Supplier also appreciate that failure in quality check serious default as it may derail entire programme and can also risk the life of users of supplied health goods.
- 16.3 CMSS will embark on stringent quality checks to ensure that tendered goods meet required standards throughout specified shelf life. For this purpose, CMSS reserves the right to carry necessary inspections /tests at any of, or any combination of or/all of following stages:

(a)At Pre-Dispatch stage.

Pre-dispatch inspection for passing the quality of the goods, would be done before direct shipment to the consignees from supplier Warehouses (in India).

(b) At Delivery Stage: inspection done once the goods reach at consignee location and before taking over supplied goods in inventory.

- (c) Post Delivery Surveillance: The Drugs/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendium sort technical specifications throughout the shelf life period of the drugs/goods. Quality Monitoring Activities may also be organized by CMSS post delivery.
- 16.4 CMSS may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality

Control.

16.5 **Inspection Methodology:**

PDI (Pre-Dispatch Inspection) as mentioned in Annexure-I means, the QA inspection/testing shall be completed prior dispatch of supplies direct to consignees/CMSS warehouses. After completion of manufacturing process, the supplier should offer goods for PDI inspection in writing to Quality Assurance department of CMSS at least 10 days before proposed inspection date. The samples of each batch will be collected and sent to designated laboratories (Government/ Private Drugs Testing Laboratories) for testing as decided by the CMSS. Handling and testing charges will be borne by CMSS. After the dispatch clearance of Quality Assurance department of CMSS, the supplier will deliver the items to the consignee or CMSS warehouses as per the schedule mentioned in the Purchase Order. If the supplier delivers/dispatches goods without completing the QA inspection, sample testing, dispatch clearance etc., CMSS shall not be processing the payments of such goods and the supplier will be solemnly responsible for the supply of such goods.

Non-PDI (Post Delivery Inspection) as mentioned in **Annexure-I** means, the supplier will deliver/dispatch the manufactured items (as per the technical specifications) directly to CMSS warehouses. The samples will be collected from the warehouse of CMSS and sent to designate Quality Control Labs in respect of supplied good satany point during specified shelf life as per decision of CMSS.

In case of failure of batches during or at any stage(indicatedat16.5), the testing charges would be claimed for the defaulting vendor.

- 16.6 The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories."Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
- 16.7 At any of Inspection/testing stage, samples which do not meet quality requirement/specifications shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods and the cost of entire batch paid will be recovered whether consumed fully/partially. Besides action may also be initiated for debarring/blacklisting against supplier for suitable period.
- 16.8 In the event of the samples of Drugs/goods supplied fails in quality tests or found to be not as per specifications at any of testing stages (as mentioned in clause no. 16.3),depending upon the type, nature and

seriousness of failure, consequences resulting from such default, availability of alternate sources, the CMSS is at liberty to either:

- (i) Ask the supplier to replace the entire quantity of relevant batches, in addition to imposition of penalty@25% of batch supply cost or
- (ii) To make alternative purchase of the items of Drugs from other approved suppliers or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier.
- (iii) In addition to (i)or(ii)above, action to debar/blacklist the supplier for suitable period, as decided by CMSS may also be initiated. In addition to forfeiture of Performance Security Deposit.
- (iv) In addition, the FDA/Drugs Control Authority of concerned State will be informed for initiating necessary action on the Tenderer in their state. Security deposit will also be forfeited without any intimation.
- (v) The decision of the CMSS or any officer authorized by CMSS, as to the quality of the supplied drugs, medicines, vaccines etc., shall be final and binding.
- 16.9 In case of supply of "NOT OF STANDARD QUALITY" goods to CMSS, the supplier shall make replace the rejected quantity by replacement within 2 months. If replaced batch is also found "NOT OF STANDARD QUALITY", the supplier shall be blacklisted for the product and no further supplies shall be accepted for the particular product category. In addition, the licensing authority will be informed for initiating necessary action on the supplier in their state. The security deposit will also be forfeited without any intimation. The warranty shall apply to replacement batches also. The decision of CMSS, as to the quality of the supplied goods shall be final and binding.
- 16.10 If the product is non-Pharmacopoeial then the supplier must provide the in house test method along with the required reference standards if asked for. The Master Formula of the products shall be provided whenever asked for.

17. PAYMENT PROVISIONS

- 17.1 No advance payments towards costs of items will be made to the Tenderer.
- 17.2 The payment towards supply of items to CMSS will be made either by means of Cheque or through RTGS (Real Time Gross Settlement System)/

Core Banking/ NEFT. The Tenderer shall furnish the relevant details in original **(Annexure-XII)** to make the payment through RTGS/Core Banking/NEFT. The payment will be in INR only.

- 17.3 All bills/ Invoices should be raised in duplicate and the bills should be drawn in the name of Central Medical Services Society, 2ndFloor, Vishwa Yuvak Kendra, Pandit Uma Shankar Dikshit Road, Chanakyapuri, New Delhi-110021 or in the name of any other authority as may be designated. Suppliers have to mention E- aushadhi PO No. and tranche/ lot on the invoice.
- 17.4 Payments for supply will be made only after completion of supply of Items ordered in the individual Purchase Order PROVIDED quality reports are acceptable. The CMSS shall endeavour to make payment within 75 days in respect of items requiring sterility tests and within 60 days in respect of items requiring non-sterility test from the date of submission of invoice or from the date of receipt of material, whichever is later along with all the relevant documents of tender.
- 17.5 Lot/Tranche/PO vise Part payments for supply will be considered only after completion of supply of at least 50% quantity ordered in the individual Purchase Order/Lot/Tranche PROVIDED original consignee receipts (or on GeM by consignee for the receipt, with original CRC to be submitted before next payment is released) are produced and the quality pass reports of Standard Quality on samples testing are received from approved laboratories of CMSS.
- 17.6 (i) Variations in prices will be admitted on account of increase or decrease in the Statutory taxes levies, such as customs duty, GST etc., on production of relevant government notification, but during scheduled delivery period only.
 - (ii) Any increase in taxes and other statutory duties/levies after the expiry of the delivery date shall be to the supplier's accounts. However, the benefit of any decrease in these taxes/duties shall be passed on to the purchaser by the supplier.

17.7 The supplier shall submit the following documents while claiming payments for supplies:

- (a) Delivery challan along with the supplies (POD)
- (b) Packing list

- (c) Certificate of analysis along with the supplies (for each batch supplied).
- (d) Itemized Invoice/ Bill in duplicate to CMSS Head Office.
- (e) Such other documents as required by CMSS.
- (f) Bidders are requested to submit their Original Invoice along with copies of Lorry Receipt/ Delivery challans and original Consignee Receipt Certificate (CRC) or such CRC to be uploaded on GeM by the consignee (if applicable) (with originals to be submitted before next payment is processed) as per format given in the tender document Annexure duly signed & stamped with other necessary documents for smooth processing of payment
- 17.8 Supplier will integrate with e- aushdhi system of CMSS and Supplier Interface Module in which selected bidders shall be required to enter/upload batch no, qty, mfg & expiry date, tranche no, invoice/challan copy etc. against PO no. Bidders are requested to submit their Original Invoice along with copies of Lorry Receipt/ Deliver challans and original Consignee Receipt Certificate (CRC) duly signed & stamped with other necessary documents for smooth processing of payment. CRC as per Annexure XXI.

18. LIQUIDATED DAMAGES AND OTHERPENALTIES:

18.1 DELAYS IN SUPPLIER'S PERFORMANCE:

(a) Delivery of the goods and performance of services shall be made by the supplier in accordance with the time schedule specified by the purchaser in its LOA/purchase order. In case the supply is not completed in the stipulated delivery period, as indicated in the LOA/purchase order or in case of non-submission of Security Deposit within the stipulated time, purchaser reserves the right either to short-close/cancel this LOA/purchase order and/or recover liquidated damage charges. The cancellation/short-closing of the LOA/Purchase order shall be at the risk and responsibility of the supplier and purchaser reserves the right to purchase balance-unsupplied quantity at the risk and cost of the defaulting vendor. This purchase at the risk and cost of the defaulting vendor can be at the same L1 cost of the tender or at higher cost and can be met through other vendors available in the present tender/contract or through any vendor from the open market. Any additional cost towards this risk purchase will be entirely borne/adjusted from running bills/demanded from the defaulting vendor.

- (b) Repeated/habitual delays by the supplier in the performance of its delivery obligations shall render the supplier liable to any or all of the following sanctions; imposition of liquidated damages, forfeiture of its performance security, and/or termination of the contract for default and purchaser reserves the right to purchase balance-unsupplied quantity at the risk and cost of the defaulting vendor.
- (c) If the suppliers are not completed in the extended delivery period, the purchase order may be short closed without any compensation to supplier and the performance security shall be forfeited.
- (d) Quantum of liquidated damages assessed and levied by the purchaser shall be final and not challengeable by the supplier.
- (e) Purchaser reserves the right to debar/blacklist the supplier for a suitable period who habitually failed to supply the goods/services in time. The decision of purchaser will be final and binding.
- 18.2 If the supply reaches the designated consignee places or CMSS Warehouse after scheduled delivery date mentioned in LOA/P.O, liquidated damages will be levied @ 2.5% per week to be applied proportionately on per day basis up to a maximum of 10% of P.O. Cost, irrespective of the fact that whether the CMSS has suffered any damage/ loss or not, on account of delay in effecting supply. If the last scheduled delivery day happens to be a holiday the supply will be accepted on the next working day without any penalty.
- 18.3 If the supply is received in damaged condition it shall not be accepted. In case of damage in the packing only, the supply may be accepted subject to purchaser's decision and after levying a penalty which may be upto 5% of cost of package received with damaged packing.
- 18.4 Timely supply is the essence of contract/ Purchase order. The drugs/medicines/items ordered are meant for key National programmes & delay in supply can have the adverse impact on patients can derail the critical National level Disease Control Programme.

For each lot/tranche, the delivery schedule (dates) are mentioned in the LOA/PO. The vendors are to make every effort to complete the

delivery of each Lot/Tranche as per delivery schedule mentioned in the LoA/PO.

In continuation to provisions of liquidated damages clause no. 18, it may be noted that:

If the vendor is not able to supply the total qty. of each lot/tranche within the scheduled delivery dates, the following may be noted:

- a. The supplier will not dispatch/supply stocks/goods after the last date of scheduled delivery of the Lot/Tranche without PO amendment issued by procurement wing.
- b. CMSS Warehouses/Direct consignees would not accept any stock/goods of any Lot/tranche beyond scheduled delivery period in absence of delivery extension PO amendment. E-Aushadhi software functionality has been made that CMSS WHs would not be able to receive the goods (GRN creation barred). These consignees will accept the stocks beyond scheduled delivery date only if Procurement wing has issued PO Amendment for delivery extension.
- c. No extension of the delivery date would be granted suo motu unless the supplier specifically asks for it. However, in a few cases, it may be necessary to grant an extension of the delivery period suo motu in the interest of the administration. In such cases, the supplier should mandatorily submit clear acceptance of the extension letter.
- d. If at any time during the currency of the contract, the supplier encounters conditions hindering delivery of goods, he shall promptly inform the concerned officer in writing. The supplier/vendor should raise request for delivery time extension well in advance i.e. at least 15 days before scheduled delivery date, should mention the likely duration within which it intends to complete the supplies and request for extension of delivery schedule accordingly. On receiving the supplier's communication, CMSS shall examine the proposal and on approval from the CA, may consider issuing delivery extension with/without LD provided: -

- i. That there are sufficient grounds for acceptance of such requests.
- ii. That there is no falling trend in prices for this item as evidenced from the fact that, in the intervening period, neither orders have been placed at rates lower than this contract nor any tender been opened where such rates have been received even though the tender is not yet decided.
- e. In such cases, for delivery extension, PO amendment would be issued and the supplier should mandatorily supply the goods in extended time period.
- f. Vendors are strictly advised not to deliver/transport any consignment reaching beyond scheduled delivery date without proper PO amendment issued by Procurement wing of CMSS, as it would not be received by consignees. CMSS shall not process any bills of such supplies if made beyond LOA/PO delivery schedule and without any PO amendment. For such actions, vendor would be solely responsible.
- g. If the supplier again fails to deliver the balance quantity within extended time, CMSS reserves the rights/options to procure the undelivered quantity from other approved supplier available in the contract at the same rates (with no financial implication and without regular tender to save time) or from open market at the risk & cost of the defaulting supplier (which may be with financial implication) or grant further extension if deemed fit.

Note- Vendors may note that it may not be necessary that each request for extension in delivery dates is accepted and scheduled delivery date is extended by CMSS.

- h. After completion of complete LD period, if the supplier/vendor still fails to deliver goods (or a part of it) within extended timelines, actions against the supplier/vendor may be initiated for default in supplies as per terms & conditions stipulated in the tender including:
 - i. CMSS reserves the rights/options to short close the delayed lot/tranche undelivered without going for purchase of balance quantity or

ii. Short close the delayed lot/tranche and go for procurement of the undelivered quantity from other approved supplier available in the contract at the same rates (with no financial implication) or from open market at the risk & cost of the defaulting supplier (which may be with financial implication).

For repeated defaults in delivery in same or various POs, to debar such habitual defaulting vendor for suitable period.

Note: - In event of Force majeure reasons/ situations as explained herein at clause no. 18, this clause would not be operated.

19.WARRANTY

- 19.1 The supplier shall warrant that goods/items to be supplied shall be new and free from all defects and faults in material, workmanship and manufacturing and shall be of the highest grade and consistent with the established and generally accepted standards for materials of the type ordered and shall perform in full conformity with the specifications. Supplier shall warrant that goods supplied will meet and maintain the technical specification throughout specified shelf life. The supplier shall be responsible for any defects that may develop under proper storage/ use, arising because of improper quality of API, Excipients in packaging material etc. manufacturing/packaging details from faulty materials, manufacturing or workmanship or otherwise and shall remedy such defects at his own cost when called upon to do so by the purchaser who shall state in writing in what respect stores faulty.
- 19.2 The portion of clause16.8 (i)to(v)would also apply in case the goods/items supplied doesn't match to shelf life.
- 19.3 Replacement under warranty clause shall be made by the Supplier within 60 days period, free of all charges at site including freight, insurance and other incidental charges.
- 19.4 If any defect is not remedied within a reasonable time the purchaser may proceed to procure such defective quantities at the Supplier's risk and cost from other tenderer or open market, but without prejudice to may other rights which the purchaser may have against the contract in respect of such defects.

20. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF DELAYS/ DEFAULT/ TERMINATION/ PART CANCELLATION/SHORT CLOSURE:

- 20.1 If the samples do not conform tender specifications, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the receipt of the letter from the CMSS. Such stock shall be taken back at the expense of the Tenderer. The CMSS has the right to destroy such "NOT OF STANDARD QUALITY DRUGS" if the Tenderer does not take back the goods within the stipulated time. The CMSS will arrange to destroy the "NOT OF STANDARD QUALITY DRUGS" after the expiry of 30 days mentioned above without further notice ,and shall also collect demurrage charges calculated at the rate of 0.5% perweekonthe value of the drugs rejected till such time stipulated.
- 20.2 The CMSS will be at liberty to terminate, without assigning any reasons there of, the contract either wholly or in part or short closed on 30days notice. The Tenderer will not be entitled for any compensation what so ever in respect of such termination besides forfeiture of Security Deposit and purchaser reserves the right to purchase balance- unsupplied item at the risk and cost of the defaulting vendor.
- 20.3 For infringement of the stipulations of the contract, for non performance/ compliance of contractual terms or for other justifiable reasons, the contract may be terminated either wholly, or in part or short closed. By the CMSS and the Tenderer shall be liable to pay for all losses sustained by the CMSS in consequence of the termination which may be recovered personally from the Tenderer or from his properties, as per rules besides forfeiture of Security Deposit.
- 20.4 In the event of making Alternative Purchase, as specified in Clause 13(f), Clause 14.2(a), Clause 16.8 and other clauses here in , penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the CMSS, in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained n the process, shall be recovered from the Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.
- 20.5 In all the above conditions, the decision of the CMSS shall be final and binding.

21.SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

22. PROHIBITION OF INFLUENCING CMSS BY THE BIDDER:

- (i) No bidder shall contact or influence the CMSS or its employees on any matter relating to its bid from the time of bid opening to the time the contract is awarded.
- (ii) Any effort by a bidder to influence the CMSS in the bide valuation, bid comparison or contract award decisions may result in rejection of the bidder's bid.
- (iii) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Evaluation Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to be a rextraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Evaluation Committee, shall be sufficient reason to disqualify the bidder.
- (iv) Not with standing anything contained in clause (iii) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

23. **RESOLUTION OFDISPUTES**

- (j) The CMSS and the supplier shall make every effort or solve, amicably by direct informal negotiation any disagreement or dispute arising between the tender or in connection with the contract.
 - (ii) In case of a dispute or difference arising between the CMSS and a supplier relating to any matter arising out of or connected with this agreement, such dispute or difference shall be settled in accordance with the Arbitration and ConciliationAct, 1996. The venue of arbitration shall be New Delhi.

24. JURISDICTION

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of New Delhi only.

<u>Annexure-I</u>

CENTRAL MEDICAL SERVICES SOCIETY- 110021

TENDERFORTHESUPPLY OF INJ. ARTESUNATE, ACT AL DRUGS & ACT SP DRUGS TO CMSS FOR THE YEAR 2022-23

LIST OF PRODUCT & THEIR TECHNICAL SPECIFICATIONS

Sch. No.	Drug Name	Unit	Approx. Tender Quantity in Units
I	Inj. Artesunate	Nos. (Vials)	28414
11	ACT-AL- Adult	Nos. (Pack)	17242
	ACT-AL- (9-14 Yrs)	Nos. (Pack)	9865
IV	ACT-AL- (4-8Yrs)	Nos. (Pack)	9865
V	ACT-AL- (6M-3 Yrs)	Nos. (Pack)	9865
VI	ACT-SP- Adult	Nos. (Pack)	106793
VII	ACT-SP- (9-14 Yrs)	Nos. (Pack)	53566
VIII	ACT-SP- (5-8 Yrs)	Nos. (Pack)	49774
IX	ACT-SP- (1-4 Yrs)	Nos. (Pack)	45982
Х	ACT-SP- (0-1 Yrs)	Nos. (Pack)	26485

Delivery Terms:

(a) The delivery shall be on DDP (Destination basis).

(b) The delivery (In tranche wise manner):-

Sch. No	Item	UOM	Quantity	Delivery Time
1	Inj. Artesunate	Nos. (Vials)	28414	Tranche I: 50% supply within 90days of placing LOA. Tranche II: 50% supply within 91- 180 days of placing LOA.
II	ACT-AL- Adult	Nos. (Pack)	17242	Tranche I: 100% supply within 90days of placing LOA
III	ACT-AL- (9-14 Yrs)	Nos. (Pack)	9865	Tranche I: 100% supply within 90days of placing LOA
IV	ACT-AL- (4-8Yrs)	Nos. (Pack)	9865	Tranche I: 100% supply within 90days of placing LOA
V	ACT-AL- (6M-3 Yrs)	Nos. (Pack)	9865	Tranche I: 100% supply within 90days of placing LOA
VI	ACT-SP- Adult	Nos. (Pack)	106793	Tranche I: 50% supply within 90days of placing LOA. Tranche II: 50% supply within 91- 180 days of placing LOA.
VII	ACT-SP- (9-14 Yrs)	Nos. (Pack)	53566	Tranche I: 100% supply within 90days of placing LOA

VIII	ACT-SP- (5-8 Yrs)	Nos. (Pack)	49774	Tranche I: 100% supply within 90days of placing LOA
IX	ACT-SP- (1-4 Yrs)	Nos. (Pack)	45982	Tranche I: 100% supply within 90days of placing LOA
Х	ACT-SP- (0-1 Yrs)	Nos. (Pack)	26485	Tranche I: 100% supply within 90days of placing LOA

Annexure 1A– Technical Specifications Annexure 1B – Consignee Location

Allocation:-100 % quantities allocated to L1 bidder for all schedules.

Pre Dispatch/ Post Dispatch Testing :- Pre Dispatch Inspection

Annexure –1A

Technical Specification of Artesunate Injection Kit under NCVBDC

Particulars	Description
A. Specific requirements	Artesunate Injection Kit consists of a vial of Artesunate Injection; an ampoule of 5% Sodium Bicarbonate Injection; an ampoule of Sodium Chloride Solution and Disposable Syringe along with Disposable needle. The individual items contained in the product shall also be currently registered in India having valid drug manufacturing license issued by relevant Indian license issuing authority.
	Artesunate Injection:
	Description:
	Artesunate Injection contains a sterile powder containing Artesunate.
	Each vial shall contain - Artesunate IP 60 mg
	The injection is reconstituted as per manufacturer instructions, immediately before use.
	The quality of Artesunate injection should conform to the requirements of Indian Pharmacopoeia, latest edition and must be accompanied by in-house test reports of the batch supplied.
	(I.P stands for Indian Pharmacopoeia)
Labeling:	The label on each vial shall conform to the requirements of Drugs & Cosmetics Act 1940 and Rules made thereund and as amended from time to time.
	The label shall indicate "NVBDCP, Dtc.GHS SUPPLY- NOT FOR SALE".
Packing: Primary Package	5 ml Vial (IP type 1 clear) (Containing Artesunate Powder for injection) closed with 20 mm Bromobutyl Rubber Pl and Sealed with flip off seal and plastic overcap.
Sodium Bicarbo	nate Injection:
Description:	A clear, colourless solution.
	Each ampoule shall contain 1 ml of Sodium Bicarbonate Injection I.P. (5%W/v). The quality of Sodium Bicarbonate injection should conform to the requirements of Indian Pharmacopoeia, lates edition and must be accompanied by in-house test reports of the batch supplied.
2	(I.P stands for Indian Pharmacopoeia)

Labelling:	The label on each vial shall conform to the requirements of Drugs & Cosmetics Act 1940 and Rules made thereunde and as amended from time to time.
	The label shall indicate "NVBDCP, Dtc.GHS SUPPLY- NOT FOR SALE".
Packing: Primary Package:	IP Type 1 clear plain glass ampoules. Each ampoule shall contain 1 ml of Sodium Bicarbonate injection I.P. (5%w/v). The ampoule should be transparent to permit visual inspection of the contents.
Sodium Chlorid	le Injection:
Description:	A clear, colourless solution. Each ampoule shall contain 5 ml of Sodium Chloride Injection I.P. (0.9%W/v).
	The quality of Sodium Chloride injection should conform to the requirements of Indian Pharmacopoeia, latest edition and must be accompanied by in-house test reports of the batch supplied. (<i>I.P stands for Indian Pharmacopoeia</i>)
Labelling:	The label on each vial shall conform to the requirements of Drugs & Cosmetics Act 1940 and Rules made thereunder and as amended from time to time.
	The label shall indicate "NVBDCP, Dte.GHS SUPPLY- NOT FOR SALE".
Packing: Primary Package:	IP Type 1 clear plain glass/FFS ampoule. Each ampoule shall contain 5 ml of Sodium Chloride injection I.P. (0.9%w/v). The ampoule should be transparent to permit visual inspection of the contents.
Disposable Syrin	ge and Disposable Needle:
Description (Disposable Needles):	Sterile Hypodermic Needles for Single Use comprise of a length of hypodermic grade stainless steel tube connected to a hub that is designed to mate with a syringe or an IV set. They shall conform to the standards given in IS 10654:2002. The other end of the tube is sharpened at the tip as per IS requirements. The tube is covered with a shield made from polypropylene. The hub fabricated from poly propylene is colour coded as per the requirements of ISO 6009. The union of the hub and needle tube is carried out with epoxy adhesive. This medical device in conjunction with Syringe is intended for immediate use for administration of injectable preparations. They are supplied sterile and pyrogen—free and not to be re-sterilized or reused.
	The Hypodermic needles shall comply with the following standards regarding Dimensions:

Labeling: (Primary)	The label shall conform to the requirements of Drugs & Cosmetics Act 1940 and Rules made thereunder and amended from time to time.
	The label shall indicate "NVBDCP, Dte.GHS SUPPLY- NOT FOR SALE".
Packing: Primary Package:	 Each syringe and needle shall be packed and sealed separately in a primary container. The material of each container should not have detrimental effects on the contents. The material and design should be such as to ensure: The maintenance of sterility under dry, clean and adequately ventilated storage conditions; The minimum risk of contamination of the contents during opening of the container and removal of the contents; Adequate protection of the contents during normal handling, transit and storage; That once opened, the container cannot be easily resealed, and it should be obvious that the container has been opened.
	Paper-PVC Blister:
	PVC Film: Transparent, clear, food grade, blister forming PVC film, film gauge- 200microns, PE coating: 25 microns.
	Hard tempered Blister paper, VMCH coated, Thickness: 0.025mm
Secondary Package:	The primary package should be packed in boxes for easy handling, transport and distribution. The box may contain primary packages. It shall be fabricated from Millboard/ grey board/ cardboard with a minimum of bursting strength of 400gsm.
Labelling on Shipper Package:	The label shall conform to the requirements of Drugs & Cosmetics Act 1940 and Rules made thereunder and a amended from time to time.
Secondary Package	e for Atresunate Injection + Sodium bicarbonate Injection + Sodium Chloride Injection:
Description	One vial of Artesunate Injection, one ampoule of Sodium bicarbonate Injection and one ampoule of Sodium Chloride Injection are packed in PVC blisters sealed, thermo-formated trays having high rigidity and sufficient impact strength to provide break resistance packaging.
	The tray along with Instructions for reconstitution and administration of Artesunate Injection should be packed in a box for easy handling, transport and distribution. It shall be fabricated from Millboard/ grey board/ cardboard with a minimum of bursting strength of 300gsm.

Labelling for secondary packaging:	The label on secondary pack shall conform to the requirements of Drugs & Cosmetics Act 1940 and Rules made thereunder and as amended from time to time.
packaging.	The Primary, Secondary and Tertiary packaging label of Inj. Artesunate kit shall indicate "NVBDCP, Dte.GHS SUPPL" NOT FOR SALE".
	The secondary packages of Artesunate Injection + Sodium Bicarbonate Injection + Sodium Chloride
Packing for Shipper Package:	Injection and that of Syringes + needles shall be packed in weather resistant triple walled insulated corrugated 5- ply cartons, each ply having strength of minimum 150gsm. It should be fabricated from virgin quality 'A' grade material. Burst factor of individual ply should be not less than 22. GSM of the shipper should be not less than 13 Kg/cm ² . Overall dimensions of the carton should be such that the product does not get damaged during transportation and storage.
Shelf Life of Artesunate Injection Kit:	Minimum 24 months, at least 5/6 th of the shelf life must remain at the time of shipment. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.
	The expiry date of the Artesunate Injection Kit shall be the same as that of Artesunate Injection being the constituent of product with the shortest shelf life.
Numbering of shipper packaging:	All boxes should be numbered consecutively. Shipping documents should be included in the box labeled number 1 (consignee wise).
Qualification of the Manufacturer:	The Bidder shall furnish a certificate from the competent Regulatory Authority that the manufacturer of the pharmaceutical product is licensed to manufacture these products. The manufacturing facility must conform to GMP standards. In case of medical devices the manufacturing facility must conform to the standards given in ISO 13485 and Schedule M-III of Drugs & Cosmetic Act.
Recalls	If products must be recalled because of problems with product quality or adverse reactions to the drug, the Supplier will be obliged to notify the purchaser providing full details about the reason leading to the recall and shall take steps to replace the product in question at its own cost with a fresh batch of acceptable quality, or withdraw and give a full refund if the product has been taken off the market due to safety problems.
Model Inserts:	A common insert containing information of all products included in Inj. Artesunate Kit with regards to use, adverse drug reactions and precautions (to be observed while taking the drug) should be a part of each secondary pack.



Melly <u>Technical Specifications approved as on 03 October 2022</u>

Aspect				Decude			
1. FINISHED PHA	RMACEUTICAL	PRODUCT (EDD	2)	Requirement			
	IN TRACEOTICAL	FRODUCT (FPP	1				
1.1 Product identification and description	ARTEMETHER - LUMEFANTRINE co-formulated tablet for oral administration						
	LUMEFANTRI	LUMEFANTRINE 120 mg					
		Recommended regimen by weight and age					
	d	u, matt inished t	ablets with abre	ak line on one sid	yellow coloured, circular de and plain on the othe	, uncoated, flat face r side.	
	The packing sh	nould be as unde	er for different ag	ge groups based	on Kg body weight.		
	Co-formulated tablet	5 - 14 kg (6 months- <3 years)	15-24 kg (≥ 3-8 years)	25-34 kg (≥ 9-14 years)	> 34 kg (> 14 years)		
	Dose	20 mg / 120 mg twice daily for 3 days		60 mg /360 mg twice daily for 3 days	80 mg /480 mg twice daily for 3 days		
			Pack size	The same and the second state in the			
	20 mg Artemether +120mg Lumefantrine	6	12	18	24		
	Colour of the pack	Yellow	Green	Red	White		
	recommended	er in dispersible dose only.	e formulation of	dry syrup. For	dry syrup, dosage to	be given as per	
2 Packaging Protective function	All packaging	dose only. must be design	ned to protect th	an dasara form			
	All packaging throughout the all the doses recognizable s primary, secon	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia	ned to protect the e. ACTs should course in a w ackaging must uv packaging in	ne dosage form be prepackagec ell-designed blis be tamper-evide	and to render it suitable into course-of-therapy ster pack, with the indiv	e for the intended pack sizes, contair ridual doses in ea	
Protective function	All packaging throughout the all the doses recognizable s primary, secor closure system	must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia a st hat approvi	hed to protect the e. ACTs should course in a wackaging must ury packaging ir ed	ne dosage form be prepackagec ell-designed blis be tamper-evide	and to render it suitable t into course-of-therapy	e for the intended pack sizes, contair ridual doses in ea	
Protective function	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct of	must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia a s that approvis contact with the	ned to protect the course in a wackaging must ury packaging ir ed. a dosage form)	ne dosage form be prepackaged ell-designed blis be tamper-evide n terms of mater	and to render it suitable I into course-of-therapy ster pack, with the indiv ent. Products must be rial and size and with t	e for the intended pack sizes, contain idual doses in es supplied in the sa he same containe	
Protective function 2.1 Primary Packs Packaging	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct c Primary packa of administratic	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia n as that approve contact with the ging materials m on. Containers m	ned to protect the e. ACTs should course in a wackaging must iry packaging ir ed. e dosage form) ust be consider	ne dosage form be prepackaged ell-designed blis be tamper-evide terms of mater	and to render it suitable into course-of-therapy ster pack, with the indiv	o for the intended pack sizes, contain ridual doses in ea supplied in the sa he same containe	
Protective function 2.1 Primary Packs Packaging naterials 2.2 Primary Packs	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct of Primary packag of administratic manufacturing aging	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia n as that approve contact with the ging materials m processes.	ned to protect th e. ACTs should course in a w ackaging must iny packaging ir ed. a dosage form) nust be consider nust not interact	ne dosage form be prepackaged ell-designed blis be tamper-evide n terms of mater ed safe for use w with contents or l	and to render it suitable the into course-of-therapy ter pack, with the indivi- nt. Products must be rial and size and with t with the dosage form and have been adverselyaffe	o for the intended pack sizes, contain ridual doses in ea supplied in the sa he same containe	
Protective function 2.1 Primary Packs Packaging materials 2.2 Primary Packs	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct of Primary packag of administratic manufacturing aging	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia n as that approve contact with the ging materials m processes.	ned to protect th e. ACTs should course in a w ackaging must iny packaging ir ed. a dosage form) nust be consider nust not interact	ne dosage form be prepackaged ell-designed blis be tamper-evide terms of mater	and to render it suitable the into course-of-therapy ter pack, with the indivi- nt. Products must be rial and size and with t with the dosage form and have been adverselyaffe	o for the intended pack sizes, contain ridual doses in ea supplied in the sa he same containe	
Protective function	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct of Primary packag of administratic manufacturing aging The primary packag ckaging	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia n as that approve contact with the ging materials m on. Containers m processes.	ned to protect the e. ACTs should course in a wackaging must my packaging in ed. a dosage form) hust be consider hust not interact ontain 10 course	ne dosage form be prepackaged ell-designed blis be tamper-evide n terms of mater ed safe for use w with contents or l es of the specified	and to render it suitable I into course-of-therapy iter pack, with the indivi- ent. Products must be rial and size and with t with the dosage form and have been adverselyaffe	o for the intended pack sizes, contain ridual doses in ea supplied in the sa he same containe	
Protective function 2.1 Primary Packs Packaging materials 2.2 Primary Packs Packaging Type 2.3 Secondary Pa Packaging type	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct to Primary packa, of administratic manufacturing aging The primary pa tackaging Each box containst	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia n as that approve contact with the ging materials m on. Containers m processes.	ned to protect the e. ACTs should course in a wackaging must my packaging in ed. a dosage form) hust be consider hust not interact ontain 10 course	ne dosage form be prepackaged ell-designed blis be tamper-evide n terms of mater ed safe for use w with contents or l	and to render it suitable I into course-of-therapy iter pack, with the indivi- ent. Products must be rial and size and with t with the dosage form and have been adverselyaffe	o for the intended pack sizes, contain ridual doses in ea supplied in the sa he same containe	
Protective function 2.1 Primary Packa Packaging materials 2.2 Primary Packa Packaging Type 2.3 Secondary Pa	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct to Primary packag of administration manufacturing aging The primary pa ckaging Each box conta aging	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia na st that approv. contact with the ging materials m processes. ackage should co aining 10 primar	hed to protect the e. ACTs should course in a wackaging must ury packaging in ed. a dosage form) nust be consider nust not interact ontain 10 course y packages (10*	ne dosage form be prepackaged ell-designed blis be tamper-evide n terms of mater ed safe for use w with contents or l es of the specified 10) of the specified	and to render it suitable I into course-of-therapy ster pack, with the indi- ent. Products must be rial and size and with t with the dosage form and have been adverselyaffe I age group. ed age group.	o for the intended pack sizes, contain ridual doses in ea supplied in the sa he same containe	
Protective function 2.1 Primary Packa Packaging materials 2.2 Primary Packa Packaging Type 2.3 Secondary Pa Packaging type 2.4 Tertiary Packa	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct to Primary packag of administration manufacturing aging The primary pa ckaging Each box conta aging Each box conta aging Primary, Secon SUPPLY- NOT	dose only. must be design e stated shelf-life of a treatment subunits. All pandary and tertia na st that approv. contact with the ging materials m processes. ackage should co aining 10 primar aining 10 second ndary and Tertia I FOR SALE". 4	hed to protect the e. ACTs should course in a wackaging must ury packaging must ed. a dosage form) nust be consider nust not interact ontain 10 course y packages (10* dary packages (10*	ne dosage form be prepackaged ell-designed blis be tamper-evide n terms of mater ed safe for use w with contents or l es of the specified 10) of the specified 100 ⁺ 10) of the spe build be marked a mended during t	and to render it suitable I into course-of-therapy ster pack, with the indi- ent. Products must be rial and size and with t with the dosage form and have been adverselyaffe age group. ed age group. ecified age group. s follows (specify): "NVE	for the intended pack sizes, contain idual doses in ea supplied in the sa- he same containe for the intended ro cted by	
Protective function 2.1 Primary Packa Packaging materials 2.2 Primary Packa Packaging Type 2.3 Secondary Pa Packaging type 2.4 Tertiary Packa Packaging type Marking Storage conditions	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct c Primary packa, of administratic manufacturing aging The primary packa, of administratic manufacturing aging Each box conta aging Each box conta Primary, Secor SUPPLY- NOT children weig	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia in as that approve contact with the ging materials m on. Containers m processes. ackage should co aining 10 primar aining 10 second ndary and Tertia f FOR SALE". / hing <5 kg (or	hed to protect the e. ACTs should course in a wackaging must iny packaging must a dosage form) hust be consider nust not interact ontain 10 course y packages (10* dary packages (10* dary packages (10* contain 10 course y packages (10* dary packages (10*)	ne dosage form be prepackaged ell-designed blis be tamper-evide n terms of mater ed safe for use w with contents or l es of the specified 10) of the specified 100*10) of the specified nended during to geb in contrastion	and to render it suitable I into course-of-therapy ster pack, with the indi- ent. Products must be rial and size and with t with the dosage form and have been adverselyaffe age group. ed age group. ecified age group. s follows (specify): "NVE	a for the intended pack sizes, contain idual doses in ea supplied in the sa- he same containe for the intended ro cted by	
Protective function 2.1 Primary Packs Packaging materials 2.2 Primary Packs Packaging Type 2.3 Secondary Pa Packaging type 2.4 Tertiary Packs Packaging type 2.4 Tertiary Packs Packaging type Marking Storage conditions luring transport	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct c Primary packag of administratic manufacturing aging The primary packag of administratic manufacturing aging Each box conta aging Each box conta Primary, Secor SUPPLY - NOT children weig Recommended Product.	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia in as that approve contact with the ging materials m processes. ackage should co aining 10 primar aining 10 second ndary and Tertia T FOR SALE". A hing < 5 kg (or d temperature ar conform to the re	hed to protect the e. ACTs should course in a wackaging must iny packaging must ed. a dosage form) nust be consider nust not interact ontain 10 course y packages (10* dary packages (10* And not recomm contain of a and humidity cond	he dosage form be prepackaged ell-designed blis be tamper-evide n terms of mater ed safe for use w with contents or l es of the specified 10) of the specified 100*10) of the specified build be marked a mended during transitions during transitions during transitions	and to render it suitable into course-of-therapy iter pack, with the indiv- ent. Products must be rial and size and with t with the dosage form and have been adverselyaffe lage group. ed age group. ecified age group. a colour	b for the intended pack sizes, contain ridual doses in ea supplied in the sa- he same containe for the intended ro cted by BDCP, Dte.GHS egnancy and for endations of the	
Protective function 2.1 Primary Packs Packaging materials 2.2 Primary Packs Packaging Type 2.3 Secondary Pa Packaging type 2.4 Tertiary Packs Packaging type 2.4 Tertiary Packs Packaging type Marking Storage conditions Juring transport .abeling	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct of Primary packag of administratic manufacturing aging The primary packag of administratic manufacturing aging Each box conta aging Each box conta Primary, Secor SUPPLY- NOT children weig Recommended Product.	dose only. must be design e stated shelf-life of a treatment subunits. All pa ndary and tertia in as that approve contact with the ging materials m processes. ackage should co aining 10 primar aining 10 second ndary and Tertia T FOR SALE". A hing < 5 kg (or d temperature ar conform to the re	hed to protect the e. ACTs should course in a wackaging must iny packaging must ed. a dosage form) nust be consider nust not interact ontain 10 course y packages (10* dary packages (10* And not recomm contain of a and humidity cond	he dosage form be prepackaged ell-designed blis be tamper-evide n terms of mater ed safe for use w with contents or l es of the specified 10) of the specified 100*10) of the specified build be marked a mended during transitions during transitions during transitions	and to render it suitable i into course-of-therapy iter pack, with the indivent. Products must be rial and size and with t with the dosage form and have been adverselyaffe age group. ed age group. ecified age group. ecified age group. s follows (specify): "NVE the first trimester of pro- g colour. sport as per IP recomme	b for the intended pack sizes, contain ridual doses in ea supplied in the sa- he same containe for the intended ro cted by BDCP, Dte.GHS egnancy and for endations of the	
Protective function 2.1 Primary Packs Packaging naterials 2.2 Primary Packs Packaging Type 2.3 Secondary Pa Packaging type 2.4 Tertiary Packs Packaging type 2.4 Tertiary Packs Packaging type Marking Storage conditions luring transport abeling . Instructions for use	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct of Primary packag of administratic manufacturing aging The primary packag of administratic manufacturing aging Each box conta Brimary, Secon SUPPLY- NOT children weig Recommended Product. The label shall of amended from ti r use: and warnings an	dose only. must be design e stated shelf-life of a treatment subunits. All pa dary and tertial a sthat approvi- contact with the ging materials m on. Containers m processes. ackage should co aining 10 primar aining 10 primar indary and Tertial r FOR SALE". A hing < 5 kg (or d temperature ar conform to the re- me to time.	hed to protect ff e. ACTs should course in a wackaging must iny packaging in ed. a dosage form) hust be consider hust not interact ontain 10 course y packages (10* dary packages (10* dary packages (10* contain not recomm <6 months of a hd humidity cond equirements of D	the dosage form be prepackaged ell-designed blis be tamper-evide in terms of mater ed safe for use w with contents or l es of the specified 10) of the specified 100*10) of the specified build be marked a mended during trans- itions during trans- trugs & Cosmetics essary (e.g. not re	and to render it suitable i into course-of-therapy iter pack, with the indivent. Products must be rial and size and with t with the dosage form and have been adverselyaffe age group. ed age group. ecified age group. ecified age group. s follows (specify): "NVE the first trimester of pro- g colour. sport as per IP recomme	e for the intended pack sizes, contain idual doses in ea supplied in the sa he same containe for the intended ro cted by BDCP, Dte.GHS egnancy and for endations of the ide thereunder and	
Protective function 2.1 Primary Packa Packaging materials 2.2 Primary Packa Packaging Type 2.3 Secondary Pa Packaging type 2.4 Tertiary Packa Packaging type Marking Storage conditions during transport Labeling 3. Instructions fo	All packaging throughout the all the doses recognizable s primary, secor closure system aging (in direct of Primary packag of administratic manufacturing aging The primary packag of administratic manufacturing aging Each box conta aging Each box conta BupPLY- NOT children weig Recommended Product. The label shall of amended from ti r use: and warnings an r children weigh	dose only. must be design e stated shelf-life of a treatment subunits. All pa dary and tertial a sthat approvi- contact with the ging materials m on. Containers m processes. ackage should co aining 10 primar aining 10 primar indary and Tertial r FOR SALE". A hing < 5 kg (or d temperature ar conform to the re- me to time.	hed to protect ff e. ACTs should course in a wackaging must iny packaging in ed. a dosage form) hust be consider hust not interact ontain 10 course y packages (10* dary packages (10* dary packages (10* contain not recomm <6 months of a hd humidity cond equirements of D	the dosage form be prepackaged ell-designed blis be tamper-evide in terms of mater ed safe for use w with contents or l es of the specified 10) of the specified 100*10) of the specified build be marked a mended during trans- itions during trans- trugs & Cosmetics essary (e.g. not re	and to render it suitable I into course-of-therapy iter pack, with the indiv- ent. Products must be rial and size and with t with the dosage form and have been adverselyaffe I age group. ed age group. ed age group. ecified age group. s follows (specify): "NVE the first trimester of pro- g colour. sport as per IP recommen- s Act 1940 and Rules ma	e for the intended pack sizes, contain idual doses in ea supplied in the sa he same containe for the intended ro cted by BDCP, Dte.GHS egnancy and for endations of the ide thereunder and	

Technical Specification of co-formulated tablet of Artemether + Lumefantrine (ACT-AL) under NCVBDC

Storage & use	As determined in stability studies, must be stated on the package insert, giving both lower and upper limits, when applicable.
5. Quality Control Sta	ndards and compliance with specifications
Pharmacopoei almonograph	The product must comply with Indian pharmacopoeia, latest version and must be accompanied by in-house test report of the batch supplied.
6. Shelf life	
Shelf-life	Minimum 24 months. At least 5/6th of the minimum shelf life must remain at the time of delivery to the consignee. The supplier will provide manufacturer's stability test data substantiating the claimed shelflife in the offered package.

	Technical Specific	ation of Combi Bliste	r Packs of ACT-SP for	r different age group ur	Ider NCVBDC
Age groups =>	Infant i.e. < 1year	1-4 Years	5-8 Years	9-14 Years	Adults
Age-group wise colour code of Combi Blisters =>	PINK COLOR	YELLOW COLOR	GREEN COLOR	RED COLOR	WHITE COLOR
	Total dose of Artesunate –75 mg divided over three days, Sulphadoxine Pyremethamine (250 mg + 12.5mg) single dose	Total dose of Artesunate – 150mg divided over three days, Sulphadoxine Pyremethamine – (500mg+25mg) single dose	Total dose of Artesunate – 300mg divided over three days, Sulphadoxine Pyremethamine (750mg+37.5mg) single dose	Total dose of Artesunate – 450mg divided over three days, Sulphadoxine Pyremethamine (1000mg+50mg) single dose	Total dose of Artesunate – 600mg divided over three days, Sulphadoxine Pyremethamine – (1500+75)mg single dose
Description of Drug / product A)	Each Combi Blister Pack : containing 3 tablet of Artesunate (each tablet of Artesunate 25mg strength) and 1 tablet of Sulphadoxine Pyremethamine (250mg + 12.5mg)	Each Combi Blister Pack : containing 3 tablets of Artesunate (50 mg each) and 1 tablet of Sulphadoxine Pyremethamine (500mg+25mg)	Each Combi Blister Pack containing 3 tablets of Artesunate (100mg each) and 1 tablet of Sulphadoxine Pyremethamine (750mg+ 37.5mg)	Each Combi Blister Pack containing 3 tablets of Artesunate 150 mg and 2 tablets of Sulfadoxine Pyremethamine (500mg+ 25mg)	Each Combi Blister Pack containing 3 tablets of Artesunate (each 200mg) and 2 tablets of Sulphadoxine Pyremethamine (750+37.5)mg each or 3 tablets of Sulphadoxine Pyremethamine (500mg+25mg) each
	First Row (Day 1)	First Row (Day 1)	First Row (Day 1)	First Row (Day 1)	First Row (Day 1)
B) Each Row	One tablet of Artesunate (25 mg) and one tablet of Suphadoxine- Pyremethamine (250 mg +12.5 mg)	One tablet of Artesunate (50 mg) and One tablet of Sulphadoxine Pyremethamine (500+25mg)	One tablet of Artesunate (100mg) and one tablet of sulphadoxine Pyremethamine (750mg+ 37.5)mg	One tablets of Artesunate (150 mg) and two tablets of Sulphadoxine Pyremethamine (500+25mg)	One tablet of Artesunate (200 mg) and two tablets of Sulphadoxine pyremethamine (750+37.5) mg each three tablets of Sulphadoxine Pyremethamine (500+25) mg each
No. of ablets :	Second Row (Day 2)	Second Row (Day 2)	Second Row (Day 2)	Second Row (Day 2)	
adiets .	One tablet of Artesunate (25mg)	One tablet of Artesunate (50mg)	One tablet of Artesunate (100mg)	One tablet of Artesunate (150mg)	Second Row (Day 2) One tablet of Artesunate (200mg)
	Third Row (Day 3)	Third Row (Day 3)	Third Row (Day 3)	Third Row (Day 3)	Third Row (Day 3)
	One tablet of Artesunate (25mg)	One tablet of Artesunate (50mg)	One tablet of Artesunate (100mg)	One tablet of Artesunate (150mg)	One tablet of Artesunate (200mg)
CAUTION:	The blister strip should be superscribed that SP is not to be given to children				

	Artesunate of 25mg, 50mg, 100mg, 150mg & 200mg as:
C)	Artesunate 25mg IP tablet ; Artesunate 50mg IP tablet ; Artesunate 100mg IP tablet ; Artesunate 150mg IP tablet; Artesunate 200mg IP tablet
Pharmacopoeial Requirement	Tablets Sulfadoxine Pyremethamine Combination: containing above strength (i.e. Sulfadoxine I.P. 250mg and Pyremethamine I.P. 12.5mg per tablet ; Sulfadoxine I.P. 500 mg and Pyremethamine I.P. 25mg per tablet and Sulfadoxine I.P. 750 mg and Pyremethamine I.P. 37.5mg per tablet) as per IP latest version.
	The product must be accompanied by in-house test reports of the batch supplied. (IP stands for Indian Pharmacopoeia)
	Tablet Artesunate: Minimum Two years
D) Shelf	Tablet Sulfadoxine + Pyremethamine: Minimum two years.
Life/ Efficacy	Each Pack will bear shelf life of minimum 2 years on the pack with manufacturing and expiry date.
	At least 5/6th of the minimum shelf life must remain at the time of delivery to the consignee. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.
	All the packs in different groups will have definite colors as indicated above.
	The tablets will be placed in three rows with transparent top. Each row should be clearly marked as Day 1, Day 2 and Day 3 giving number of tablets in each row.
E. Packing &	Each pack should indicate dose schedule per kg body weight for both Tablet Artesunate and Tablet Sulphadoxine- Pyremethamine i.e. AS-4 mg/kg body weight and 25mg/ kg bw of sulphadoxine + 1.25 mg per kg bw of pyrimethamine respectively.
Marking	Marking: Printing/marking on Blister/Catch cover/corrugated box and pack will be as per Drug & Cosmetics Act 1940 and Rules made thereunder and as amended from time to time.
	Manufacturing and Expiry dates of Artesunate and Sulfadoxine - Pyremethamine tablets should be written separately on the Blister Pack/Catch Cover.
	Each Blister Strip will be stuffed in a paper catch cover. 25 Blister Strips will be placed in a pack and 100 such acks will be packed in a corrugated box. Each Blister Strip/Catch Cover/Pack and corrugated Box should be marked "NVBDCP, Dte.GHS SUPPLY- NOT FOR SALE" in contrasting colour.
~	
. Labelling	The label shall conform to the requirements of Drugs & Cosmetics Act 1940 and Rules made thereunder and as amended from time to time.
6. Final acking	Supplies shall be securely packed in normal trade packing of corrugated boxes to avoid loss or damage during the transit by rail/road.
	Technical Specifications approved as on 03 October 2022

Annexure 1-B

Details of CMSS warehouses (Consignee Location):

ACT-SP (All age group)

Annexure-1

CMSS Warehouse	0-1 Years	1 to 4 years	5 to 8 years	0 to 14 years	4.3.14
Hyderabad	113	248		9 to 14 years	Adult
Patna	10	and the second sec	338		1688
Raipur	9500	23	31	40	156
Navi Mumbai		15849	17074	18299	35521
	2880	5546	5817	6087	9885
Ahmedabad	27	60	81	103	406
Chandigarh	6	13	17	22	87
Ranchi	2533	3256	3738		
Bangalore	14	30	41		10982
Trivendram	5	11	41	52	204
Bhopal	135	296	404		77
Jajpur	10000	18736	19868	511	2019
Jaipur	9	21		21001	36903
Chennai	1		28	36	140
Lucknow		9_	12	15	59
	327	720	982	1243	4908
Kolkata	923	1166	1328	1490	3758
Grand Total	26485	45982	49774	53566	106793

ACT-AL (All age group)

CMSS Warehouse	6M to 3 years	3 to 8 Years	9 to 14 Years	Adult
Guwahati	3798	3798	3798	7620
Agartala	6067	6067	6067	9622
Total	9865	9865	9865	17242
Grand Total	19730	19730	19730	34483

Artesunate Injection

CMSS Warehouse	Quantity
Guwahati	3500
Agartala	3500
Jajpur	3000
Raipur	1414
Ranchi	5000
Bhopal	5000
Hyderabad	2000
Kolkata	5000
Grand Total	28414

Details of CMSS warehouses (Consignee Location):

	CMSS Warehouse & Mapped States								
Sr No	Warehouse Location	States/UT's covered by the Warehouse	Address						
1	Agartala, (Tripura)	Tripura	CMSS, CWC Complex, Hapania, Near ONGC complex, Opposite of Satsangha Ashram, Agartala, Tripura Pin- 799014						
2	Ahmedabad, (Gujarat)	Gujarat	CMSS, Central warehousing corporation premises, Opposite P&T Colony, Teen Batti Road, Near Shahalam Gate, Shahalam, Ahmedabad, Gujarat Pin- 380028						
3	Bangalore, (Karnataka)	Karnataka	CMSS, Ministry of Health & Family Welfare, Central warehousing corporation premises, APMC Yard, Yeshwanthapur, Bangalore, Pin- 560022						
4	Bhopal, (M.P.)	Madhya Pradesh	CMSS, Central warehousing corporation premises, Godown no. 1A, Near railway cabin no. 3, Chhola road, Nishatpura, District: Bhopal Pin- 462 010. Landline No. 0755-2508050						
		Chandigarh							
		Punjab							
	Zirakpur, (Punjab)	Haryana	CMSS, Ground Floor, Warehouse No. B014/3433, Godown Area. 35 Feet Road, Village Bhabat, Thana						
5		Himanchal Pradesh							
		Jammu & Kashmir,	Zirakpur, SAS NAGAR, Punjab Pin- 140603						
		Leh Ladakh							
		Uttarakhand							
		Tamil Nadu	CMSS C/o Central warehousing corporation Warehous						
6	Chennai,	Pondicherry	no: 11C Opposite to Varadharaja Theatre Chitlapakkam,						
-	(Tamil Nadu)	Andaman & Nicobar Islands	Chrompet, Chennai Pin- 600064						
7	Bhuneshwar (Odisha)	Odisha	CMSS, 326, Khata No -456/948 Mouza-Johal, PO/PS- Pahal, Dist-Khorda, Bhubaneswar, Odisha- 751032						
8	Delhi	Delhi	CMSS, KH. No. 81, Village Bamnoli, Sec -28, Dwarka, Delhi-110075						
		Assam	-						
		Arunachal Pradesh	4						
0	Guwahati,	Meghalaya	CMSS, EPIP Complex, CWC premises, Opp. Emami,						
9	(Assam)	Nagaland	Amingaon, Guwahati, Pin- 781 031						
		Sikkim							
		Manipur	-						
	Hydonobod	Mizoram Telangana							
10	Hyderabad, (Telangana)	Andhra Pradesh	Behind Gandhibhavan, Nampally, Hyderabad-500001						
11	Jaipur, (Rajasthan)	Rajasthan	CMSS C/O CWC, Plot NoSPL-1296, EPIP, Sitapura Ind. Area, Goner Road, Jaipur, Rajasthan-Pin- 302022						
12	Kolkata, (West Bengal)	West Bengal	CMSS C/o Central Warehousing Corporation, Bonhooghly, RIC Estate, Kolkata, West Bengal- 700108						

The details of CMSS warehouses are given below:-

	CMSS Warehouse & Mapped States								
Sr No	Warehouse Location	States/UT's covered by the Warehouse	Address						
13	Lucknow, (U.P.)	Uttar Pradesh	CMSS C/o Central Warehousing Corporation, Naveen Galla Mandi, Sitapur Road Lucknow UP-226020						
14	Mumbai, (Maharashtra)	Maharastra Goa Dadra and Nagar Haveli Daman and Diu	 CMSS C/O- Central Warehousing Corporation, GN. 01, Regional Office Mumbai, Sector-20, NR, Turbe RLY Station, Vashi - Navi Mumbai-400703 Landline No. 022- 27830009. 						
15	Patna, (Bihar)	Bihar	CMSS C/O- Central Warehousing Corporation, Katra Bazar, Bazar Samiti, Patna City Pin -800008.						
16	Raipur, (Chhattisgarh)	Chattisgarh	CMSS, C/O- Central Warehousing Corporation, Near Harish Petrol Pump, Rauabhata, Birgaon, Raipur, Pin- 493221						
17	Ranchi, (Jharkhand)	Jharkhand	CMSS C/O- Central Warehousing Corporation, Near OTC ground, Ranchi, Pin no. 834005						
18	Trivandrum , (Kerala)	Kerala Lakshadweep	CMSS C/O- Central Warehousing Corporation Kinfra Aplarel Park Menamkulam, Trivandrum Kerala Pin- 695586 Landline No. 0471-2704470						

CMSS reserve to right the change the consignee at any time if required.

Annexure II TENDER FORWARDING LETTER

Date:

To, DG&CEO, Central Medical Services Society 2nd Floor, VishwaYuvak Kendra, Pandit Uma Shaker Dixit Marg, Chankyapuri, New Delhi- 110021

Sub: Acceptance of Terms& Conditions of Tender.

Tender No: CMSS/PROC/2022-23/NVBDCP/031

Name of Tender: - Online Tender for Procurement of **Inj. Artesunate**, **ACT AL Drugs & ACT SP Drugs** FOR NVBDCP.

Dear Sir,

1.I/We have downloaded/obtained the tender document(s)for the above mentioned

'Tender/Work' from the web site(s)namely:

as per your advertisement, given in the above mentioned website(s).

2.I/We here by certify that I/we have read the entire terms and conditions of the tender documents (Including all document like annexure(s),schedule(s),etc.,),which form part of the contract agreement and I/we shall abide here by the terms /conditions /clauses contained therein.

3.The corrigendum(s) issued from time to time by your department/organization too has also been taken into consideration, while submitting this acceptance letter.

4.1 /We here by unconditionally and unequivocally accept the tender conditions of above mentioned tender document(s)/ corrigendum(s) In its totality/entirety.

5.I/We do here by declare that our Firm has not been blacklisted/debarred by any Govt. Department/Public sector undertaking for the quoted product from any procurement agency or as a whole.

6. I/We here by declare that bid will remain valid for a period of 150 days after opening of Tender bid/packet1

7. I/We certify that all information furnished by our Firm is true & correct and in the event that the information is found to be incorrect/untrue or found violated, then your department/organization shall without giving any notice or reason therefore or summarily reject the bid or terminate the contract, without prejudice to any other rights or remedy including the forfeiture of the full said earnest money deposit absolutely.

Yours Faithfully, (Signature of the Tenderer, with Official Seal)

Annexure-III

DETAILS OF E.M.D. SUBMITTED

We herewith	submit the E.M.D. of Rs			in th	he form	of RTGS/ N	NEFT/DD/
FDR/Bank	Guarantee/Insurance	Security	Bonds		vide	documer	nt Ref.
No	Date	ed:					Bank:
		in	favour	of	Central	Medical	Services

Society for the following items:-

	Name of the product	UOM	Quantity in Bid	Amount of EMD Payable (in INR) for 100% quantity	Quantity Quoted	% of the Bid Quantity	Amount of EMD
Ι	Inj. Artesunate	Nos. (Vials)	28414	12680			
II	ACT-AL- Adult	Nos. (Pack)	17242	14286			
	ACT-AL- (9-14 Yrs)	Nos. (Pack)	9865	6842			
IV	ACT-AL- (4-8Yrs)	Nos. (Pack)	9865	4952			
V	ACT-AL- (6M-3 Yrs)	Nos. (Pack)	9865	1971			
VI	ACT-SP- Adult	Nos. (Pack)	106793	76250			
VII	ACT-SP- (9-14 Yrs)	Nos. (Pack)	53566	27950			
VIII	ACT-SP- (5-8 Yrs)	Nos. (Pack)	49774	19103			
IX	ACT-SP- (1-4 Yrs)	Nos. (Pack)	45982	11558			
Х	ACT-SP- (0-1 Yrs)	Nos. (Pack)	26485	6139			

Annexure-IV

PROFORMA FOR PERFORMANCE STATEMENT

(FOR A PERIOD OF LAST 2 YEARS)

Name of firm______ Sr. No. of the Product ______ Name of the Product ______

Sch. No	Name of Product	Year 2020-21	Year 2021-22	Quantity manufact ured and marketed	UOM	Name and full address of the Purchaser
1	2	3	4	5	6	7
I						
II						

Note:

- 1. Proof for the manufacturing (BMR)/ importing of the items quoted to be produced, if demanded.
- 2. Copies of purchase orders in support of performance statement may be uploaded along with this Annexure-IV.

Signature of Tenderer Name in Capitals Date: Seal: Signature of Statutory Auditor Name in Capitals Date Seal

Annexure-V

ANNUAL TURN OVERSTATEMENT

 The Annual Turnover (Sales) of M/s.__________ for the past three years are given below and certified that the statement is true and correct.

 Sl. No.
 Financial Year
 Turnover in Lakhs (Rs)

 1.
 2019-2020

 2.
 2020-2021

 3.
 2021-2022

 Total

Average Turn-over Per Annum in the last three years mentioned above-Rs.___Lakhs.

Signature of Auditor/ Chartered Accountant

Seal:

Date

(Name in Capital)

Annexure- VI

:

LIST OF ITEMS QUOTED & THEIR PRODUCTION CAPACITY

- 1. Name of the firm
- 2. Address of the firm as given in Drug license :
- 3. Details of Endorsement for all products quoted:

Sch No	Item Code	Drug Name	UOM	Quantity Tendered	Quantity quoted			Average Quantity	
						Capacity	2020-21	2021-22	Manufactured
1	2	3	4	5	6	7	8A	8B	9
				TOTAL					

Date:

Authorized Signatory:

<u>Annexure-VII</u>

<u>CHECK LIST</u>

Packet 1

Attached Pg. No. in bid

1.	Checklist – Annex-VII (Clause 6 n)	Yes	No
2.	EMD in the form of DD/ BG as per Annex-III / MSME certificate for exemption(Clause 6 a)	Yes	No
3.	Certificate by MSME/ SSI units in support of being a MSE/ SSI unit. (Clause 6 a)	Yes	No
4.	Duly attested photocopy of Manufacturing License (valid on the date of tender opening) for the product duly approved by the Licensing Authority for each and every product quoted. (Clause 6 c)	Yes	No
5.	Authorization letter nominating a responsible person of the tenderer to transact the business with the Tender inviting Authority. (Clause 6 d)	Yes	No
6. 7.	Market Standing Certificate issued by the Licensing Authority (Clause 6 e) Valid WHO-GMP Certificate (valid on the date of tender opening) (Clause 6 f) & COPP	Yes	No
8.	Non Conviction Certificate issued by the Drugs Controller (Clause 6 h)	Yes	No
9.	Annual Turnover Statement for 3 Years i.e. 2019-20, 2020-21 and 2021-22 (Clause 6 j) (Annex-V)	Yes	No
10.	Copies of Balance Sheet & Profit & Loss Account for last three years i.e. 2019-20, 2020-21 and 2021-22 (Clause 6 k)	Yes	No
11.	Proforma for Performance Statement (Annex-IV) (Clause 6 x)	Yes	No
12.	List of items quoted and their production capacity – Annex-VI (Clause 6 l)	Yes	No
13.	Mandate Form for RTGS	Yes	No

		CMSS/PROC/2022-23/NVBDCP/031						
	Annex-XII. (Clause 6 y)							
14	The Tender document signed by the		Yes		No			
1	tenderer in all pages with office seal. (Clause 6 o)		105		110			
	tenderer man pages with onice sean (shadse o o)							
15.	Long Term Stability Data of the quoted products (at least for 3 batches) to support specified shelf life. (Clause 6 m)		Yes		No			
16.	Capacity and Quality Certificate issued		Yes		No			
	by the Licensing Authority (Clause 6 g)							
17.	Undertaking that Firm is not blacklisted or debarred		Yes		No			
	from any Govt. Agency (Clause 4 e, 6 t)							
10	Neterine d Herdenteline her MCE	[]	Vee		N-			
18.	Notarized Undertaking by MSE		Yes		No			
	(Annex – VIII) (Clause 6 a)							
19.	No Deviation Certificate (Clause 6 q)		Yes		No			
			L					
20.	Tender forwarding letter (Annexure-II) (Clause 6 b)		Yes		No			
21.	Near Relative Certificate (Annexure-XVIII) (Clause 6 r)		Yes		No			
22.	Supplied Quantity (PO Copies) (minimum 40% of the		Yes		No			
22.	quoted quantity (Clause 6 h)		ies		INO			
	quoteu quantity) (clause o nj							
22	Draft Artwork (Clause 6 a)		Yes		No			
23.	Draft Artwork (Clause 6 s)		ies		INO			
24.	Certificate i.r.o Class I & Class-II Local Bidder Annexure		Yes		No			
	XIX (Clause 4 a, 6 u)							
				······································				
25.	Annex- XIX (Undertaking for Compliance to Ministry of		Yes		No			
	Finance, DOE order No- 6/18/2019-PPD dated							
	23.07.2020(Clause 6 w)							

NOTE:

Bidders are requested to submit all documents with the bid as shown as checklist (Annexure - VII). NO CLARIFICATIONS may be sought from bidders and incomplete bid may be summarily rejected at sole responsibility of bidder(s). CMSS decision in this regard will be final and binding.

M/s_____ For Self and Firm / Company Ltd.

Signature and Seal

<u>Annexure-VIII</u>

NOTARISED UNDERTAKING BY MSE COMPANIES

(In 20- Rupees stamp paper)

I _____, S/o _____, Proprietor / Partner / Managing Director of ______ (Proprietary Concern / Firm / Company Ltd.) execute this Undertaking for myself and on behalf of ______ (Proprietary Concern / Firm / Company Ltd.).

2. Whereas, CMSS (Tender Inviting Authority) has invited Tender for supply of Drugs and medicines for the year 2022-2023 and in pursuant to the conditions in the tender documents. M/s ______ (Proprietary Concern/ Firm / Company Ltd.), having its Office at ______ is

exempted from payment of Earnest Money Deposit as indicated in the **Annexure-III** of tender document.

3. And whereas, in pursuant to the conditions in Clause Nos. 9.2, 9.3 & 9.4 of the tender, the Earnest Money Deposit can be forfeited by the Tender Inviting Authority in case of violation of any of the conditions and for non-performance of the obligation under tender document.

4. In consideration of exempting M/s._____ (Proprietary Concern/ Firm / Company Ltd.) from payment of Earnest Money Deposit as indicated in the **Annexure-III** of tender document, I undertake to pay the said sum without any demur on receipt of demand issued by the tender inviting authority.

M/s_____

For Self and Firm / Company Ltd.

Signature and Seal

Witness:-

(2)

<u>Annexure-IX</u>

Central Medical Services Society

2nd Floor, VishwaYuvak Kendra, Pandit Uma Shankar Dixit Marg, Teen Murti Road, Opp. Police Station, Chanakyapuri, New Delhi- 110021, Tel: 011-214109005 011-21410906 Email; gmproc.cmss@gmail.com

LETTER OF ACCEPTANCE

No. CMSS/PROC/2022-23/NVBDCP/031

Date _____

То,	
M/s	
Address:	
Attn:	
Phone:	
Email	
	$(\mathbf{N}_{1},\ldots,\mathbf{n}_{n})$

(Kind Attn: _____ (Name), _____ Designation)

Sub: Acceptance of Tender for supply of INJ. ARTESUNATE, ACT AL Drugs & ACT SP Drugs under NVBDCP to CMSS

 Ref: 1) CMSS Tender No. CMSS/PROC/2022-23/NVBDCP/031 opened on ______

 2) Your Ref. No. ______ dated ______ in response to above mentioned tender.

Dear Sir,

1. I am pleased to inform you that your offer in response to above mentioned tender for supply of ITEMS FOR NVBDCP has been accepted for following items:

Sch	Items	Quantity	Unit	Ex-	GST	GST	Transport	Total unit	Grand	
No.	Description			Works per Unit (Rs.)	(%)	(Rs)	& any other charges (Rs.)	price (all incl) (Rs.)	Total (Rs.)	
1										
2										
Grand Total										

- 2. You are requested to deposit Security Deposit @ 3% of the total value by NEFT/ RTGS/ Bank Guarantee/Demand Draft/ Banker's Cheque and enter into an Agreement, as per the format given in **Annex-X** of the Tender document, within 15 days from the date of receipt of this letter. The Security Deposit shall be valid as per tender clause no12 from the date of commencement.
- 3. Please convey your acceptance to this LOA within 03 days of issue, else it will be presumed that you are not keen to accept the LOA and CMSS may proceed for allocation of quantity to other bidder and with other actions stipulated in referred Tender document.

- 4. All other terms and conditions will be applicable as per Tender document no. *CMSS/PROC/2022-23/NVBDCP/031* and subsequent amendments to it.
- 5. Delivery Period: As specified in Annexure I of Tender Document.
- 6. Manufacturing license as per Annexure A and Consignee List as per Annexure B.
- 7. Payment Terms: Within 75 days of supplies in respect of items requiring sterility tests and within 60 days of supplies for other items.

Encl: - Annexure A: List of manufacturing license and site address. Annexure B: List of consignee.

General Manager (Procurement)

Copy to :

- 1. General Manager (LSC), CMSS
- 2. General Manager (Finance), CMSS
- 3. General Manager (QA), CMSS
- 4. All Consignees concerned through Programme Division.

Annexure A to LOA No: Supplier: M/s _____

<u>Annexure - A</u>

LIST OF MANUFACTURING LICENSES & SITE ADDRESSES					
Sr. No.	Item Code	Item Description	Manufacturing Site Address	Manufacturing License No.	Remarks
1					
2					
3					

<u>Annexure – X</u>

LONG TERM AGREEMENT (LTA) NO.: CMSS/PROC/2022-23/NVBDCP/031/LTA E- STAMP CERTIFICATE NO.:

LTA Validity: From _____ to ____

TERMS OF AGREEMENT

THIS AGREEMENT made the...... day of, year between **Central Medical Services Society**, 2nd Floor, Vishwa Yuvak Kendra, Pt. Uma Shankar Dikshit Marg, Teen **Murti Marg, Opposite Police Station Chankaya Puri, New Delhi-110021** (here in after "the Purchaser") of the one part and (Name of Supplier) of...... (Address and Country of Supplier) (Here in after called "the Supplier") of the other part:

WHEREAS the Purchaser is desirous that certain Goods and ancillary services viz; **Procurement of Inj. ARTESUNATE, ACT AL Drugs & ACT SP Drugs under NVBDCP** in the Tender Reference No. **CMSS/PROC/2022-23/NVBDCP/031, Dt_____**(Brief Description of Goods and Services) and has accepted a bid by the Supplier for the supply of those goods and services for the sum of....... (Contract Price in Words and Figures) (Hereinafter called "the Contract Price").

WHEREAS the Supplier confirms that it is qualified, ready, willing and able to supply/services the **Procurement of Inj. ARTESUNATE, ACT AL Drugs & ACT SP Drugs under NVBDCP** in accordance with the terms and conditions of this Agreement.

1. **DEFINITIONS**

Commencement Date means _____

Expiry Date means _____

Products, in singular form Product, means the item(s), as described and detailed above, provided by the Supplier to CMSS from time to time pursuant to this agreement.

Tender means Tender No. Tender No: **CMSS/PROC/2022-23/NVBDCP/031** from CMSS to the Supplier, to quote for the cost of supply of the Products to CMSS.

Long Term Agreement, as abbreviated to Agreement or LTA, means this Agreement between the Parties, to provide Products, including its Annexes, however with due consideration of the order of precedence among the LTA and individual Annexes.

Parties means CMSS and the Supplier, their successors and assigns and where not repugnant to the context, their servants or agents.

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. LTA DOCUMENTS:

The following documents shall be deemed to form and be read and construed as part of this Agreement, viz.:

- (a) This LTA
- (b) The Notice Inviting Tender
- (c) Terms and Conditions of Tender Document as given in Tender No: CMSS/PROC/2022-23/NVBDCP/031 dt. _____
- (d) The Minutes of Pre-Bid meeting and corrigendum issued.
- (e) Schedule of Requirement.
- (f) The Technical Specification
- (g) The Supplier's Offer including Enclosures, Annex etc.
- (h) Any other document listed in the supplier's bid and replies to queries, clarifications issued by the purchaser, such confirmations given by the tenderer which are acceptable to the purchaser and the entire Addendum issued as forming part of the contract.
- (i) The Letter of Acceptance issued by the purchaser.

2. PURPOSE OF LTA:

- 1.1 The Purchaser hereby covenants to pay the Supplier in consideration of the provision of the goods, the Contract Price at the times and in the manner prescribed by this Agreement.
- 1.2 Brief particulars of the Products or goods which shall be supplied / provided by the Supplier are as under.

Sch	Items	Quantity	Unit	Ex-	GST	GST	Transport &	Total unit	Grand
No.	Description			Works	(%)	(Rs)	any other	price (all	Total
				per Unit			charges	incl) (Rs.)	(Rs.)
				(Rs.)			(Rs.)		
1									
2									
Grand Total									

1.3 The supplier agrees that his supplies are subject to terms and conditions details contained in LTA documents mentioned above. The supplier appreciates that the supplies are meant for public health system in the country and hence will agree to supply the goods of good quality as per standards in a timely manner as specified as per tender terms and conditions. The supplier has already given its no deviation (clause-by-clause compliance) for the subject terms and conditions.

3 . Manufacturing License and Site License and Site Address:

As per Annexure A.

IN WITNESS where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed,	Sealed	and	Delivered	by	the	said	(For	the
Purchas	er)							
in the p	resence o	of						
Signatu	re							

Name	
Address	
Signed, Sealed and Delivered by the Said	(For the
Supplier)	
in the presence of	
Signatura	
Signature	
Name	Address
Annexure A to LTA No: Supplier: M/s	

<u>Annexure - A</u>

Annexure A to LTA No: Supplier: M/s

LIST	LIST OF MANUFACTURING LICENSES & SITE ADDRESSES										
Sr. No.	Item Code	Item Description	Manufacturing Site Address	Manufacturing License No.	Remarks						
1											
2											
3											

<u> Annexure - XI</u>

CENTRAL MEDICAL SERVICES SOCIETY

Ministry of Health & Family Welfare

(Government of India)

2nd Floor, Vishwa Yuvak Kendra, Pt. Uma Shankar Dikshit Marg, Teen Murti Marg, Opposite Police Station Chankaya Puri, New Delhi-110021, India

PURCHASE ORDER

PO No: CMSS/PROC/2022-23/NVBDCP/031/PO/.....

Dated: _____

Subject:	Purchase Order for supply of Inj. ARTESUNATE, ACT AL Drugs & ACT SP Drugs under NVBDCP								
Ref :	Long Term Agreement No: CMSS/PROC/2022-23/NVBDCP/031/LTA/dated	••							

Dear Sir,

Please supply following quantities for the items specified as per the technical specifications and terms & conditions of the Long Term Agreement referred above:

Sr.No	Item	Item	Quantity	Unit	Ex	GST	GST	Transportation	Rate Per	Total	Destination
	Code	Description	Accepted		Works	(%)	(Rs)	Charges	Unit	Value	
			by the		Price			(Rs)	(Landed	(Rs)	
			Purchaser		per				Price)(Rs)		
					Unit						
					(Rs)						
1											As per
											Annex 1
2											As per
											Annex-1

- 1. All the Terms & Conditions of the Agreement signed by you on acceptance of your tender are applicable.
- 2. Delivery Period: 90 Days from the date of LOA.
- 3. Manufacturing license as per Annexure A and site address as per Annexure B.
- 4. Payment Terms: Within 75 days of supplies in respect of items requiring sterility tests and within 60 days of supplies for other items.

General Manager (Procurement)

Copy to :

- General Manager (LSC), CMSS
 General Manager (Finance), CMSS
- 3. General Manager (QA), CMSS
- 4. All Consignees through Programme Division.

<u>Annexure - A</u>

Annexure A to PO No: Supplier: M/s

	CONSIGNEE-LIST											
Sr. No.	Item Description	Consignee Location	Consignee Address	Quantity	UOM	Remarks						
1												
2												
3												

<u>Annexure-B</u>

Annexure B to PO No: Supplier: M/s

LIST	LIST OF MANUFACTURING LICENSES & SITE ADDRESSES										
Sr. No.	Item Code	Item Description	Manufacturing Site Address	Manufacturing License No.	Remarks						
1											
2											
3											

Annexure -XII

MANDATE FORM

01	Company Name	
02	Postal Address of the company with Telephone No., Fax No. and Mail ID.	
03	Name of the Managing Director / Director / Manager Mobile No. / Phone No. E-mail ID.	
04	Name and Designation of the authorized company official Mobile No.	
	E-mail ID	

Date:Company Seal & SignaturePlace:(Name of the person signing & designation)

Mandate Form contd..

01	Name of the Bank.	
	Branch Name& address.	
	Branch Code No.	
	Branch Manager Mobile No.	
	Branch Telephone no.	
	Branch E-mail ID	
02	9 digit MICR code number of the bank	
	and branch appearing on the MICR	
	cheque issued by the bank.	
03	IFSC code of the Branch	
04	Type of Account (Current / Savings)	
05	Account Number (or enner in Cherry	
05	Account Number (as appear in Cheque	
	book)	

(in lieu of the bank certificate to be obtained , please **<u>attach the original cancelled</u> <u>cheque</u>** issued by your bank for verification of the above particulars).

I /We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reasons of incomplete or incorrect information, I would not hold M/s. Central Medical Services Society (CMSS) responsible. I have read the conditions of the tender/agreement entered and agree to discharge the responsibility expected of me / from the company as a tenderer /successful tenderer.

Date: Company Place:			Company Sea	ıl Signa	(Name		1	on designation)	
CERTIFIED CORRECT A			PARTICULARS	FURNISHED	ABOVE	BY	THE	COMPANY	ARE

Bank Seal with address.	Signature of the authorized official of the bank.

<u>Annexure-XIII</u>

PACKET -2 PRICE -BID

CENTRAL MEDICAL SERVICES SOCIETY NEW DELHI – 110021

Tender for Procurement of Inj. ARTESUNATE, ACT AL Drugs & ACT SP Drugs under NVBDCP

Schedule of price bid in the form of BOQ_XXXX.xls uploaded online.

(Below sheet is only for reference)

ender No:					SP DRUGS FOR N	VBDCP			
	CMSS/PROC/2022-23/NVBDCP/	031							
idder Name									
					PRICE SCHEDUL				
This BOQ	template must not be modified/re	placed by the bidd	er and the same :		ed after filling the rel der Name and Value		e the bidder is	liable to be rejected for this tender. Bidders a	re allowed to enter th
UMBER #	TEXT #	TEXT #	NUMBER #	TEXT #	TEXT	NUMBER #	NUMBER	NUMBER	NUMBER
SI. No.	Name of the Item	Location	Quantity In Tender		Quantity Offered	EX Works price per unit in Rs.	GST (In Rs.)	Transportation and any Other Charges in Rs. (Till Consignee Locations) on DDP basis, All Inclusive and firm & fixed	Total Unit Price Witi GST(In Rs.) (Col 7+ Col 8+Col 9
1	2	3	4	5	6	7	8	9	10
1.01	Inj. ARTESUNATE	1. Annex-I	28414	Nos (Vials)					3 0.00
1.02		2. Annex-I		Nos (Packs)			y		₹0.00
1.03	ACT-AL- Adult ACT-AL- (9-14 Yrs)	3. Annex-I	17242 9865	Nos (Packs)					₹ 0.00
1.01				Nos (Packs)	0		3	5	₹ 0.00
1.05	ACT-AL- (4-8Yrs)	4. Annex-I	9865	Nos (Pocks)					3 0.00
1.06	ACT AL (6M 3 Yrs)	5. Annex-I	9865	Nos (Packs)					t 0.00
	ACT-SP- Adult	6. Annex-I	106793						
1.07	ACT-SP- (9-14 Yrs)	7. Annex-I	53566	Nos (Packs)					₹ 0.00
1.08		8. Annex-I	49774	Nos (Packs)	1				₹ 0.00
1.09	ACT-SP- (5-8 Yrs) ACT-SP- (1-4 Yrs)	9. Annex-I	49774	Nos (Packs)					₹ 0.00
1.1		10. Annex-l	43302	Nos (Packs)			6	5	₹ 0.00
	ACT-SP- (0-1 Yrs)		26485						

Note:

- 1. List of Consignee warehouses as per Annex-I B.
- 2. Details of weight, volume and dimensions of shipping cartons and intermediate cartons may be provided as an additional annex to this form.

Annexure-XIV

Bank Guarantee for EMD (Format)

[The Bank shall fill in this Bank Guarantee Form in accordance with the instructions indicated.]

[insert Bank's Name, and Address of Issuing Branch or Office] Beneficiary: [insert Name and Address of Purchaser] Date: ______ BIDGUARANTEE No.: _____

We have been informed that *[insert name of the Tenderer]* (hereinafter called "the Tenderer ") has submitted to you its bid dated (hereinafter called "the Bid") for the execution of *[insert name of contract]* under Tender No.....

Further more, we understand that, according to your conditions, bids must be supported by a EMD.

At the request of the Tenderer ,we *[insert name of Bank]* hereby irrevocably under take to pay you any sum or sums not exceeding in total an amount of *[insert amount in figures]([insert amount in words]*) upon receipt by us of your first demand in writing accompanied by a written statement stating that the Tenderer is in breach of its obligation(s) under the bid conditions, because the Tenderer :

(a)has withdrawn its Bid during the period of bid validity specified by the Tenderer in the Form of Bid; or

(b) having been notified of the acceptance of its Bid by the Purchaser during the period of bid validity, (i)fails or refuses to execute the Contract Form, if required, or(ii)fails or refuses to furnish the security deposit, in accordance with the Instructions to Tenderer s.

(c) does not accept the correction of the Bid Price

(d)This guarantee will expire: (a) if the Tenderer is the successful tenderer ,upon our receipt to copies of the contract signed by the Tenderer and the performance security issued to you upon the instruction of the Tenderer ; or(b) if the Tenderer is not the successful tenderer ,upon the earlier of (i) our receipt of a copy of your notification to the Tenderer of the name of the successful tenderer ;or (ii) Twenty Eight days after the expiration of the Tenderer's Bid.

Consequently, any demand for payment under this guarantee must be received by us at the office on or before that date.

This guarantee is subject to the Uniform Rules for Demand Guarantees, ICC Publication No. 758.

[signature(s)]

Annexure-XV

Security Bank Guarantee (Format)

_____ [insert: **Bank's Name, and Address of Issuing Branch or Office**]

Beneficiary: _____ [insert: Name and Address of Purchaser]
Date: _____

PERFORMANCE GUARANTEE No.: _____

We have been informed that *[insert: name of Supplier]* (hereinafter called "the Supplier") has received a Letter of Acceptance No. *[insert: reference number of the Letter of Acceptance]* dated _______ for entering into a Rate Agreement with you, for the supply of *[insert: description of goods]*

Furthermore, we understand that, according to the conditions of the Tender, a performance guarantee is required post acceptance of letter of Acceptance.

At the request of the Supplier, we *[insert: name of Bank]* hereby irrevocably undertake to pay you any sum or sums not exceeding in total an amount of *[insert: amount in figures]* (___) *[insert: amount in words]*¹ upon receipt by us of your first demand in writing accompanied by a written statement stating that the Supplier is in breach of its obligation(s) under the Tender , without your needing to prove or to show grounds for your demand or the sum specified therein.

This guarantee shall expire no later than the ____ day of _____, 2___,² and any demand for payment under it must be received by us at this office on or before that date.

This guarantee is subject to the Uniform Rules for Demand Guarantees, ICC Publication No. 758, except that subparagraph (ii) of Sub-article 20(a) is hereby excluded.

[signature(s)]

The Guarantor shall insert an amount representing the percentage of the Price specified in the letter of Acceptance and denominated in the currency of the Contract.

Established in accordance with tender conditions taking into account any warranty obligations of the Supplier as per tender conditions The Purchaser should note that in the event of an extension of the time to perform the Contract, the Purchaser would need to request an extension of this guarantee from the Guarantor. Such request must be in writing and must be made prior to the expiration date established in the guarantee. In preparing this guarantee, the Purchaser might consider adding the following text to the form, at the end of the penultimate paragraph: "The Guarantor agrees to a one-time extension of this guarantee for a period not to exceed [six months] [one year], in response to the Purchaser's written request for such extension, such request to be presented to the Guarantor before the expiry of the guarantee."

<u>Annexure-XVI</u>

Instructions for Online Bid Submission

The tenderers are required to submit soft copies of their bids electronically on the CPP Portal, using valid Digital Signature Certificates. The instructions given below are meant to assist the tenderers in registering on the CPP Portal, prepare their bids in accordance with the requirements and submitting their bids online on the CPP portal.

More information useful for submitting online bids on the CPP Portal may be obtained at:

REGISTRATION

- 1) Tenderers are required to enroll on the e-Procurement module of the Central Public Procurement Portal (URL: <u>https://eprocure.gov.in/eprocure/app</u>) by clicking on the link "**Online tenderer Enrolment**" on the CPP Portal which is free of charge.
- 2) As part of the enrolment process, the tenderers will be required to choose a unique user name and assign a password for their accounts.
- 3) Tenderers are advised to register their valid email address and mobile numbers as part of the registration process. These would be used for any communication from the CPP Portal.
- 4) Upon enrolment, the tenderers will be required to register their valid Digital Signature Certificate (Class II or Class III Certificates with signing key usage) issued by any Certifying Authority recognized by CCA India (e.g. Sify/ n- Code/e-Mudhra etc.), with their profile.
- 5) Only one valid DSC should be registered by a tenderer .Please note that the tenderer s are responsible to ensure that they do not lend their DSC's to others which may lead to misuse.
- 6) Tenderer then logs into the site through the secured log-in by entering their user ID /password and the password of the DSC /e-Token.

SEARCHING FOR TENDER DOCUMENTS

- 1) There are various search options built in the CPP Portal, to facilitate tenderers to search active tenders by several parameters. These parameters could include Tender ID, Organization Name, Location, Date, Value, etc. There is also an option of advanced search for tenders, wherein the tenderers may combine a number of search parameters such as Organization Name, Form of Contract, Location, Date, Other keywords etc. to search for a tender published on the CPP Portal.
- 2) Once the tenderers have selected the tenders they are interested in, they may download the required documents/tender schedules. These tenders can be moved to the respective 'My Tenders' folder. This would enable the CPP Portal to intimate the tenderers through SMS /e-mail in case there is any corrigendum issued to the tender document.
- 3) The tenderer should make a note of the unique Tender ID assigned to each tender, in case they want to obtain any clarification/help from the Helpdesk.

PREPARATION OF BIDS

- 1) Tenderer should take into account any corrigendum published on the tender document before submitting their bids.
- 2) Please go through the tender advertisement and the tender document carefully to understand the documents required to be submitted as part of the bid. Please note the number of covers in which the bid documents haveto be submitted, the number of documents-including the names and content of each of the document that need to be submitted. Any deviations from these may lead to rejection of the bid.
- 3) Tenderer, inadvance, should get ready the bid documents to be submitted as indicated in the tender document/schedule and generally, they can be in PDF/XLS/RAR/DWF/JPG formats. Bid documents may be scanned with100dpi with black and white option which helps in reducing size of the scanned document.
- 4) To avoid the time and effort required in uploading the same set of standard documents which are required to be submitted as a part of every bid, a provision of uploading such standard documents (e.g. PAN card copy, annual reports, auditor certificates etc.)has been provided to the tenderers. Tenderer scan use "My Space" or "Other Important Documents" area available to them to upload such documents. These documents maybe directly submitted from the "My Space" area while submitting a bid, and need not be uploaded again and again. This will lead to a reduction in the time required for bid submission process.

SUBMISSION OF BIDS

- 1) Tenderer should log into the site well in advance for bid submission so that they can upload the bid in time i.e. on or before the bid submission time. Tenderer will be responsible for any delay due to other issues.
- 2) The tenderer has to digitally sign and upload the required bid documents one by one as indicated in the tender document.
- 3) Tenderer has to select the payment option as "offline" to pay the tender fee/ EMD as applicable and enter details of the instrument.
- 4) Tenderer should prepare the EMD as per the instructions specified in the tender document. The original should be posted/couriered/given in person to the concerned official, latest by the last date of bid submission or as specified in the tender documents. The details of the DD/any other accepted instrument, physically sent, should tally with the details available in the scanned copy and the data entered during bid submission time. Otherwise the uploaded bid will be rejected.

- 5) Tenderers are requested to note that they should necessarily submit their financial bids in the format provided and no other format is acceptable. If the price bid has been given as a standard BoQ format with the tender document, then the same is to be downloaded and to be filled by all the tenderers. Tenderers are required to download the BoQ file, open it and complete the white coloured (unprotected)cells with their respective financial quotes and other details (such as name of the tenderer). No other cells should be changed. Once the details have been completed, the tenderer should save it and submit it online, without changing the file name. If the BoQ file is found to be modified by the tenderer ,the bid will be rejected.
- 6) The server time (which is displayed on the tenderers' dashboard) will be considered as the standard time for referencing the deadlines for submission of the bids by the tenderers, opening of bids etc. The tenderers should follow this time during bid submission.
- 7) All the documents being submitted by the tenderers would be encrypted using PKI encryption techniques to ensure the secrecy of the data. The data entered cannot be viewed by unauthorized persons until the time of bid opening. The confidentiality of the bids is maintained using the secured Socket Layer128 bit encryption technology. Data storage encryption of sensitive fields is done. Any bid document that is uploaded to the server is subjected to symmetric encryption using a system generated symmetric key. Further this key is subjected to a symmetric encryption using buyers/bid openers' public keys. Overall, the uploaded tender documents become readable only after the tender opening by the authorized bid openers.
- 8) The uploaded tender documents become readable only after the tender opening by the authorized bid openers.
- 9) Upon the successful and timely submission of bids (i.e. after Clicking "Freeze Bid Submission" in the portal), the portal will give a successful bid submission message & a bid summary will be displayed with the bid no. and the date &time of submission of the bid withalother relevant details.
- 10) The bid summary has to be printed and kept as an acknowledgement of the submission of the bid. This acknowledgement may be used as an entry pass for any bid opening meetings.

ASSISTANCE TO TENDERERS

- 1) Any queries relating to the tender document and the terms and conditions contained there in should be addressed to the Tender Inviting Authority for a tender or the relevant contact person indicated in the tender.
- Any queries relating to the process of online bid submission or queries relating to CPP Portal in general may be directed to the 24x7 CPP Portal Helpdesk Ph.:0120-4200462, 0120-4001002.Mobile: 91 8826246593

.....

Annexure- XVII

No Deviation Certificate

This is to certify that the product(s) quoted_____ by our firm, M/s. _____ is as per the given technical specifications in the tender document & there is no deviation in relation to any conditions/requirements specified in the tender document.

Authorized Signatory

<u>Annexure-XVIII</u>

Near Relative Certificate

(In case of Proprietorship firm certificate will be given by the proprietor. For partnership firm certificate will be given by all the partners and in case of limited company by all the Directors of the company excluding Govt. of India/Financial Institutions nominees and independent non-official part time directors appointed by Govt. of India or the Governor of the state. Authorised signatory of bid may also sign this bid on behalf of the entire directors/ partners/ proprietor).

This is to certify that none of my/our Company Directors' near relative as defined below currently works in CMSS where I am/we are going to apply for the tender. I/We also agree to the condition that due to any breach of conditions by the company or firm or any other related person the bid submitted on behalf of the company or firm will be cancelled and bid security will be forfeited at any stage whenever it is noticed and CMSS will not pay any damage to the company or firm or the concerned person. The company or firm will also be debarred for further participation for the quoted item in CMSS for a period of one year.

The near relatives for this purpose are defined as:

- (a) Members of a Hindu undivided family.
- (b) They are husband and wife.

(c) The one is related to the other in the manner as father, mother, son(s) & son's wife (Daughter in law), daughter(s) and daughter's husband (son in law), brothers(s) and brother's wife, sister(s) and sister's husband (brother in law).

Signature/Signatures (with Stamp)

<u>ANNEXURE XIX</u>

FORMAT FOR LOCAL CONTENT DECLARATION

Tender Reference No:		Date:
Ι	, S/o, D/o, W/o	,
Resident of		do hereby solemnly affirm and declare as under:-
The local content is	_% for the	(quoted item of M/s

That I on behalf of M/s ______ will agree to abide by the terms and conditions of the Ministry of Chemicals & Fertilizers, DOP, Government of India issued vide notification no. 31026/65/2020-MD dated 30.12.2020 and DPIIT order no. P- 45021/2/2017- PPBE- II dated 16.09.2020 and calculations for local content have been done in accordance with Sr. No. 1 of DOP order no. 31026/65/2020-MD dated 30.12.2020.

That the information furnished hereinafter is correct to best of my knowledge and belief and I on behalf of M/s ______undertake to produce relevant records before the procuring entity or any authority so nominated by the Department of Pharmaceuticals. Government of India for the purpose of assessing the local content.

(Name of Firm/ Entity)

Authorized Signatory/ Statutory Auditor/ Chartered Accountant (with Company Seal/Stamp) (Refer Clause 9 of DPIIT Order dtd. 16.09.2020)

<u>Annexure XX</u>

UNDERTAKING

(On Company's Letter Head)

We, (name of bidder), having offices at

.....are participating in Bid No.

..... Dated.....

We equivocally and irrevocably undertake that,

- i) Compliance of DOE, MOF order No. 6/18/2019 PPD dated:- 23.07.2020 or any other subsequent revised order in said matter.
- ii) Compliance of Public Procurement Order 2017- revision, issued vide No. P-45021/2017-PP (BE-II) Dated:- 16/9/2020 or any other subsequent revised order in said matter.

If at any stage of tendering process, non-compliance of above orders - observed/found we will be liable for stringent actions as per the tender terms and condition including suspension/debarment from any bidding in CMSS/MoHFW tenders for two years.

M/s _____

Witness

For Self and Firm/Company Limited

1.

Signature & Seal of company

Annexure-XXI

CONSIGNEE RECEIPT CERTIFICATE

(To be given by consignee's authorized representative)

The following store(s) has/have been received in good condition:

1)	P.O No. & date:
2)	Supplier's Name:
3)	Consignee's Name & Address with telephone No. & Fax No. :
4)	Name of the items/equipment supplied:
5)	Quantity of items/equipment Supplied:
6)	Date of Receipt of items/equipment by the Consignee:
7)	Name and designation of Authorized Representative of Consignee :
8)	Signature of Authorized Representative of Consignee with date:
9)	Counter Signed by Director/MS/Dean of the concerned Hospital/Institute:

10) Seal of the Consignee:_____